{"content":"<li class=\"n-box-item date-title\" data-end=\"1560311999\" data-start=\"1560225600\" data-txt=\"Monday, December 23, 2019\">Tuesday, June 11, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3470616\" data-ts=\"1560290081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KRNT\" target=\"_blank\">KRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470616-kornitminus-5_1-on-4_34m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kornit -5.1% on 4.34M-share offering</a></h4><ul>   <li>Israel's Kornit Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital Ltd.'>KRNT</a>) is <font color=\"red\">5.1% lower</font> after hours following a disclosure that it's <a href=\"https://seekingalpha.com/pr/17541619-kornit-announces-launch-public-offering-ordinary-shares\" target=\"_blank\">offering 4.34M ordinary shares</a>.</li>    <li>Underwriters will get a 30-day greenshoe option to buy up to 651,000 more shares.</li>    <li>Book-runners are Citigroup, Goldman Sachs and Barclays, along with co-managers Needham, Stifel, William Blair and Craig-Hallum.</li>    <li>Proceed are targeted for future acquisitions (including complementary businesses, technologies or assets) and general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470616\" data-linked=\"Kornit -5.1% on 4.34M-share offering\" data-tweet=\"$KRNT - Kornit -5.1% on 4.34M-share offering https://seekingalpha.com/news/3470616-kornitminus-5_1-on-4_34m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3470616-kornitminus-5_1-on-4_34m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470615\" data-ts=\"1560289806\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470615-mattel-rejects-another-merger-bid-from-mga-entertainment-la-times\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mattel rejects another merger bid from MGA Entertainment - LA Times</a></h4><ul><li>Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) <font color=\"green\">+10.9%</font> after-hours following a <em>Los Angeles Times</em> report that the toymaker again <a href=\"https://www.latimes.com/business/la-fi-mattel-mga-merger-offer-20190611-story.html\" target=\"_blank\">rejected an unsolicited merger offer</a> from rival MGA Entertainment.</li><li>MGA founder and CEO Isaac Larian says last month he renewed his offer to merge the companies, contending MAT's problems have worsened in the year since he made his initial overture.</li><li><div><div><p>Larian has not proposed a specific offer price for MAT but says it \"absolutely\" would be at a  premium to the stock's current price.</p></div></div></li></ul><div class=\"tiny-share-widget\" data-id=\"3470615\" data-linked=\"Mattel rejects another merger bid from MGA Entertainment - LA Times\" data-tweet=\"$MAT - Mattel rejects another merger bid from MGA Entertainment - LA Times https://seekingalpha.com/news/3470615-mattel-rejects-another-merger-bid-from-mga-entertainment-la-times?source=tweet\" data-url=\"https://seekingalpha.com/news/3470615-mattel-rejects-another-merger-bid-from-mga-entertainment-la-times\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470613\" data-ts=\"1560288843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470613-play-leads-after-hours-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PLAY leads after hours losers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/MX' title='MagnaChip Semiconductor Corporation'>MX</a> <font color=\"green\">+16.9%</font>. <a href='https://seekingalpha.com/symbol/AXGT' title='Axovant Gene Therapies Ltd.'>AXGT</a> <font color=\"green\">+15.5%</font>. <a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color=\"green\">+8.7%</font>. <a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a> <font color=\"green\">+6.7%</font>. <a href='https://seekingalpha.com/symbol/NVTR' title='Nuvectra Corporation'>NVTR</a> <font color=\"green\">+5.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"red\">-16.7%</font>. <a href='https://seekingalpha.com/symbol/TAL' title='TAL Education Group'>TAL</a> <font color=\"red\">-8.7%</font>. <a href='https://seekingalpha.com/symbol/PBPB' title='Potbelly Corporation'>PBPB</a> <font color=\"red\">-4.0%</font><a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a> <font color=\"red\">-3.4%</font>. <a href='https://seekingalpha.com/symbol/KE' title='Kimball Electronics, Inc.'>KE</a> <font color=\"red\">-2.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470613\" data-linked=\"PLAY leads after hours losers\" data-tweet=\"$MX $AXGT $MAT - PLAY leads after hours losers https://seekingalpha.com/news/3470613-play-leads-after-hours-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470613-play-leads-after-hours-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470612\" data-ts=\"1560288755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470612-cymabayplus-4_8-raymond-james-fades-45-sell-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay +4.8% as Raymond James fades 45% sell-off</a></h4><ul>   <li>Raymond James has upgraded CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) to Strong Buy after today's harsh market reaction to experimental data released this morning.</li>    <li>The stock is <font color=\"green\">up 4.8%</font> after hours.</li>    <li>Shares closed the day <font color=\"red\">down 45.5%</font> after <a href=\"https://seekingalpha.com/news/3470340-cymabay-40-percent-premarket-disappointing-data-nash-candidate-seladelpar\" target=\"_blank\">disappointing data</a> from an experimental therapy for NASH, a fatty liver disease.</li>    <li>That reaction was \"overblown,\" Raymond James' Steven Seedhouse says, noting that the drug wasn't factored into his models, and that he expected the stock to recover when the market considers the probability that other aggregate improvements \"could translate into fibrosis/ballooning/inflammation benefit, irrespective of the lack of liver fat signal.\"</li>  <li>Sell-siders on average <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/sell-side-ratings\" target=\"_blank\">rate CymaBay an Outperform</a>, while <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha authors are Bullish on average</a> and its <a href=\"https://seekingalpha.com/symbol/CBAY/ratings/quant-ratings\" target=\"_blank\">Quant Rating is Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470612\" data-linked=\"CymaBay +4.8% as Raymond James fades 45% sell-off\" data-tweet=\"$CBAY - CymaBay +4.8% as Raymond James fades 45% sell-off https://seekingalpha.com/news/3470612-cymabayplus-4_8-raymond-james-fades-45-sell-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3470612-cymabayplus-4_8-raymond-james-fades-45-sell-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470607\" data-ts=\"1560287583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENT\" target=\"_blank\">ENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470607-global-eagleplus-25-on-disclosure-chairman-bought-400k-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Eagle +25% on disclosure chairman bought 400K shares</a></h4><ul>    <li>Global Eagle Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/ENT' title='Global Eagle Entertainment Inc.'>ENT</a>) is <font color=\"green\">up 24.9%</font> on heavy postmarket volume after a filing disclosing Executive Chairman Jeffrey Leddy purchased $216,000 worth of stock.</li>    <li>Leddy bought 400,000 shares on Friday at an average price of $0.54, according to the filing.</li>    <li>That brings his beneficial ownership to 1,249,284 shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3470607\" data-linked=\"Global Eagle +25% on disclosure chairman bought 400K shares\" data-tweet=\"$ENT - Global Eagle +25% on disclosure chairman bought 400K shares https://seekingalpha.com/news/3470607-global-eagleplus-25-on-disclosure-chairman-bought-400k-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3470607-global-eagleplus-25-on-disclosure-chairman-bought-400k-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470597\" data-ts=\"1560285288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTR\" target=\"_blank\">NVTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470597-nuvectra-files-u-s-application-for-expanded-label-for-algovita-scs-shares-up-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuvectra files U.S. application for expanded label for Algovita SCS; shares up 7% after hours</a></h4><ul><li>Nuvectra (NASDAQ:<a href='https://seekingalpha.com/symbol/NVTR' title='Nuvectra Corporation'>NVTR</a>) has <a href=\"https://seekingalpha.com/pr/17541484-nuvectra-files-regulatory-submission-fda-algovita-full-body-mr-conditional-approval\" target=\"_blank\">submitted an application</a> to the FDA seeking a full-body MR-conditional approval for its <a href=\"https://nuvectramedical.com/\" target=\"_blank\">Algovita SCS</a> system. It hopes to gain the regulatory nod by year-end.</li><li>Shares are up <font color=\"green\">7%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470597\" data-linked=\"Nuvectra files U.S. application for expanded label for Algovita SCS; shares up 7% after hours\" data-tweet=\"$NVTR - Nuvectra files U.S. application for expanded label for Algovita SCS; shares up 7% after hours https://seekingalpha.com/news/3470597-nuvectra-files-u-s-application-for-expanded-label-for-algovita-scs-shares-up-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3470597-nuvectra-files-u-s-application-for-expanded-label-for-algovita-scs-shares-up-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470593\" data-ts=\"1560284965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MX\" target=\"_blank\">MX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470593-magnachipplus-13_8-on-raised-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagnaChip +13.8% on raised guidance</a></h4><ul><li>MagnaChip (NYSE:<a href='https://seekingalpha.com/symbol/MX' title='MagnaChip Semiconductor Corporation'>MX</a>) <a href=\"https://seekingalpha.com/pr/17541476-magnachip-semiconductor-provides-updated-guidance-q2-2019-financial-results\" target=\"_blank\">updates</a> its Q2 outlook to revenue of at least $194M (was: $173-181M) and gross profit margin of at least 21% (was: 16-18%).</li><li>The boost comes from the OLED Display and Foundry businesses \"substantially\" exceeding the respective 30% and flat Y/Y growth from the previous guidance.</li><li>MX shares are <font color=\"green\">up 13.8%</font> after the close to $10.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470593\" data-linked=\"MagnaChip +13.8% on raised guidance\" data-tweet=\"$MX - MagnaChip +13.8% on raised guidance https://seekingalpha.com/news/3470593-magnachipplus-13_8-on-raised-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3470593-magnachipplus-13_8-on-raised-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470586\" data-ts=\"1560284713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETX\" target=\"_blank\">PETX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470586-fda-oks-new-vial-size-for-aratanas-nocita-shares-up-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs new vial size for Aratana&#39;s Nocita; shares up 8% after hours</a></h4><ul><li>Aratana Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics, Inc.'>PETX</a>) is up <font color=\"green\">8%</font> after hours in apparent response to the FDA's <a href=\"https://seekingalpha.com/pr/17541473-aratana-therapeutics-granted-fda-approval-nocita-bupivacaine-liposome-injectable-suspension\" target=\"_blank\">Veterinary Medicine division nod</a> for a 10 mL vial size for NOCITA (bupivacaine liposome injectable suspension). It was previously available in a 20 mL vial only.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470586\" data-linked=\"FDA OKs new vial size for Aratana&#39;s Nocita; shares up 8% after hours\" data-tweet=\"$PETX - FDA OKs new vial size for Aratana&#39;s Nocita; shares up 8% after hours https://seekingalpha.com/news/3470586-fda-oks-new-vial-size-for-aratanas-nocita-shares-up-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3470586-fda-oks-new-vial-size-for-aratanas-nocita-shares-up-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470579\" data-ts=\"1560284406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DASTF\" target=\"_blank\">DASTF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470579-dassault-nears-medidata-purchase-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dassault nears Medidata purchase - Bloomberg</a></h4><ul><li>Dassault Systemes (<a href='https://seekingalpha.com/symbol/DASTF' title='Dassault Systèmes SE'>OTCPK:DASTF</a>,<a href='https://seekingalpha.com/symbol/DASTY' title='Dassault Systèmes SE'>OTCPK:DASTY</a>) is nearing a deal to acquire Medidata Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/MDSO' title='Medidata Solutions, Inc.'>MDSO</a>), according to Bloomberg sources.</li><li>MDSO shares are <font color=\"green\">up 4.4%</font> after hours to $98.90.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470579\" data-linked=\"Dassault nears Medidata purchase - Bloomberg\" data-tweet=\"$DASTF $DASTY $MDSO - Dassault nears Medidata purchase - Bloomberg https://seekingalpha.com/news/3470579-dassault-nears-medidata-purchase-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3470579-dassault-nears-medidata-purchase-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470578\" data-ts=\"1560284400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470578-dave-bustersminus-16-after-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s -16% after guidance cut</a></h4><ul><li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) reports comparable sales fell 0.3% in <a href=\"https://seekingalpha.com/pr/17541489-dave-and-buster-s-achieves-9_5-percent-revenue-8_8-percent-eps-growth-first-quarter\" target=\"_blank\">Q1</a> to fall short of the consensus expectation for a 1.6% gain. The shift of the Easter holiday was blamed in part for the shortfall.</li><li>Adjusted EBITDA was up 2.4% to $98M during the quarter.</li><li>Looking ahead, D&amp;B sees full-year revenue of $1.365B to $1.390B vs. $1.37B to $1.40B prior and $1.40B consensus. Full-year net income of $103M to $113M is anticipated vs. $105M to $117M prior. 15 to 16 new D&amp;B store openings are expected for the full year.</li><li>Shares of Dave &amp; Buster's are <font color=\"red\">down 15.95%</font> in AH trading.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3470563-dave-and-busters-eps-misses-0_01-misses-revenue\" target=\"_blank\">Dave &amp; Buster's EPS misses by $0.01, misses on revenue</a> (June 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3470578\" data-linked=\"Dave &amp; Buster&#39;s -16% after guidance cut\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s -16% after guidance cut https://seekingalpha.com/news/3470578-dave-bustersminus-16-after-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3470578-dave-bustersminus-16-after-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470562\" data-ts=\"1560283459\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYX\" target=\"_blank\">AYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470562-alteryx-sets-long-term-margin-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alteryx sets long-term margin targets</a></h4><ul><li>Alteryx (NYSE:<a href='https://seekingalpha.com/symbol/AYX' title='Alteryx, Inc.'>AYX</a>) sets a long-term gross margin target of 90% to 92% during today's <a href=\"https://investor.alteryx.com/news-and-events/presentations/default.aspx\" target=\"_blank\">investor event</a>.</li><li>Operating margin is set at 35% to 40%, R&amp;D at 15% to 17%, and FCF of 30% to 35%.</li><li>AYX shares closed today <font color=\"red\">down 2.1%</font> as part of the software selloff following yesterday's pop on the Tableau acquisition.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470562\" data-linked=\"Alteryx sets long-term margin targets\" data-tweet=\"$AYX - Alteryx sets long-term margin targets https://seekingalpha.com/news/3470562-alteryx-sets-long-term-margin-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3470562-alteryx-sets-long-term-margin-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470560\" data-ts=\"1560283134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GORO\" target=\"_blank\">GORO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470560-gold-resource-launched-buy-rating-roth-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Resource launched with Buy rating at Roth Capital</a></h4><ul><li>Gold Resource Corp. (<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a> <font color='green'>+12.5%</font>) surges after Roth Capital's Jake Sekelsky started coverage with a <a href=\"https://thefly.com/thestreet/realmoney/index.php/GOROid2920479/GORO-Gold-Resource-initiated-with-a-Buy-at-Roth-Capital\" target=\"_blank\">Buy rating</a> and $6.50 price target.</li><li>Sekelsky sees GORO as a growing, financially sound company with a focus on free cash flow generation, and with a second production hub hitting stride in H2 2019, the analyst believes free cash flow generation is set to increase and that shares are set up for a re-rating.</li><li>GORO's average <a href=\"https://seekingalpha.com/symbol/GORO/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform and its <a href=\"https://seekingalpha.com/symbol/GORO/ratings/author-ratings#filter=all\" target=\"_blank\">SA Authors' Rating</a> is Bullish, but the stock's <a href=\"https://seekingalpha.com/symbol/GORO/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470560\" data-linked=\"Gold Resource launched with Buy rating at Roth Capital\" data-tweet=\"$GORO - Gold Resource launched with Buy rating at Roth Capital https://seekingalpha.com/news/3470560-gold-resource-launched-buy-rating-roth-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3470560-gold-resource-launched-buy-rating-roth-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470550\" data-ts=\"1560279854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470550-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers:  </strong>Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"green\">+13%</font>. Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <font color=\"green\">+11%</font>.  Huami (NYSE:<a href='https://seekingalpha.com/symbol/HMI' title='Huami Corporation'>HMI</a>) <font color=\"green\">+9%</font>. Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software Incorporated'>MRIN</a>) <font color=\"green\">+9%</font>. Jiayin Group (NASDAQ:<a href='https://seekingalpha.com/symbol/JFIN' title='Jiayin Group Inc.'>JFIN</a>) <font color=\"green\">+8%</font>. <strong></strong></li><strong> </strong><li><strong>Losers:  </strong>Intellicheck (NYSEMKT:<a href='https://seekingalpha.com/symbol/IDN' title='Intellicheck, Inc.'>IDN</a>) <font color=\"red\">-21%</font>. Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Corporation'>INAP</a>) <font color=\"red\">-9%</font>. Domo (NASDAQ:<a href='https://seekingalpha.com/symbol/DOMO' title='Domo, Inc.'>DOMO</a>) <font color=\"red\">-9%</font>. Gridsum (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-8%</font>. Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) <font color=\"red\">-8%</font>.<strong> </strong></li><strong> </strong></ul><div class=\"tiny-share-widget\" data-id=\"3470550\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$ANY $HEAR $HMI - Microcaps mostly among tech movers https://seekingalpha.com/news/3470550-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470550-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470548\" data-ts=\"1560279429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTX\" target=\"_blank\">UTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470548-industrials-pinned-down-weakness-among-aerospace-defense-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Industrials pinned down by weakness among aerospace/defense stocks</a></h4><ul><li>Would-be merger partners United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color=\"red\">-3.9%</font>) and Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color=\"red\">-4.9%</font>) lead industrial as well as defense and aerospace names lower a day after Pres. Trump <a href=\"https://seekingalpha.com/news/3470104-trump-voices-concerns-rtn-utx-merger\" target=\"_blank\">gave mixed signals</a> on whether he believed the deal between the companies should go forward.</li><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"red\">-1.2%</font>) is weak following a relatively disappointing aircraft order update, while the likes of Lockheed Martin, Northrop Grumman, General Dynamics (<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color=\"red\">-2.2%</font>), Harris (<a href='https://seekingalpha.com/symbol/HRS' title='Harris Corporation'>HRS</a> <font color=\"red\">-4.2%</font>) and L3 Technologies (<a href='https://seekingalpha.com/symbol/LLL' title='L3 Technologies, Inc.'>LLL</a> <font color=\"red\">-4.3%</font>) may be weighed in part amid worries about a <a href=\"https://www.wsj.com/articles/defense-consolidation-continues-as-spending-priorities-shift-11560245580\" target=\"_blank\">possible slowdown in Pentagon spending</a> highlighted in a <em>WSJ</em> article today.</li><li>Analysts say the new UTX-RTN combination could add pressure to Boeing, which has been pressuring suppliers to cut costs even as the creation of ever-larger competitors has reduced its negotiating clout.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLI' title='Industrial Select Sector SPDR ETF'>XLI</a>, <a href='https://seekingalpha.com/symbol/ITA' title='iShares U.S. Aerospace & Defense ETF'>ITA</a>, <a href='https://seekingalpha.com/symbol/XAR' title='SPDR S&P Aerospace & Defense ETF'>XAR</a>, <a href='https://seekingalpha.com/symbol/PPA' title='Invesco Aerospace & Defense ETF'>PPA</a>, <a href='https://seekingalpha.com/symbol/VIS' title='Vanguard Industrials ETF'>VIS</a>, <a href='https://seekingalpha.com/symbol/FIDU' title='Fidelity MSCI Industrials Index ETF'>FIDU</a>, <a href='https://seekingalpha.com/symbol/IFLY' title='ETFMG Drone Economy Strategy ETF'>IFLY</a>, <a href='https://seekingalpha.com/symbol/IYJ' title='iShares U.S. Industrials ETF'>IYJ</a>, <a href='https://seekingalpha.com/symbol/FXR' title='First Trust Industrials AlphaDEX ETF'>FXR</a>, <a href='https://seekingalpha.com/symbol/AIRR' title='First Trust RBA American Industrial Renaissance ETF'>AIRR</a>, <a href='https://seekingalpha.com/symbol/RGI' title='Invesco S&P Equal Weight Industrial ETF'>RGI</a>, <a href='https://seekingalpha.com/symbol/UXI' title='ProShares Ultra Industrials ETF'>UXI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3470548\" data-linked=\"Industrials pinned down by weakness among aerospace/defense stocks\" data-tweet=\"$UTX $RTN $BA - Industrials pinned down by weakness among aerospace/defense stocks https://seekingalpha.com/news/3470548-industrials-pinned-down-weakness-among-aerospace-defense-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3470548-industrials-pinned-down-weakness-among-aerospace-defense-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470541\" data-ts=\"1560277255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470541-petrobras-oks-mero-project-phase-2-development-off-brazil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras OKs Mero project phase 2 development off Brazil</a></h4><ul><li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petróleo Brasileiro S.A. - Petrobras'>PBR</a> <font color='green'>+2.8%</font>) and its partners say they have taken the <a href=\"https://www.offshoreenergytoday.com/petrobras-sanctions-second-phase-of-mero-field-development/\" target=\"_blank\">final investment decision to develop</a> the second phase of the Mero project in the pre-salt area of the Santos Basin offshore Brazil.</li><li>\"The decision to launch Mero 2 comes as a new milestone in this large-scale project that will develop the giant oil resources of the Mero field,\" estimated at 3B-4B barrels says Arnaud Breuillac, head of exploration and production at partner Total (<a href='https://seekingalpha.com/symbol/TOT' title='TOTAL S.A.'>TOT</a> <font color='green'>+1.6%</font>).</li><li>PBR owns 40% of the Libra project, Royal Dutch Shell (NYSE:<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>) and TOT each own 20%, and China National Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/PTR' title='PetroChina Company Limited'>PTR</a>) and Cnooc (NYSE:<a href='https://seekingalpha.com/symbol/CEO' title='CNOOC Limited'>CEO</a>) each hold 10% stakes in the project.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470541\" data-linked=\"Petrobras OKs Mero project phase 2 development off Brazil\" data-tweet=\"$PBR $RDS.A $TOT - Petrobras OKs Mero project phase 2 development off Brazil https://seekingalpha.com/news/3470541-petrobras-oks-mero-project-phase-2-development-off-brazil?source=tweet\" data-url=\"https://seekingalpha.com/news/3470541-petrobras-oks-mero-project-phase-2-development-off-brazil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470540\" data-ts=\"1560276896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470540-western-digital-cuts-ties-huawei\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital cuts ties with Huawei</a></h4><ul><li>Western Digital (<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a> <font color='green'>+1.1%</font>) <a href=\"https://asia.nikkei.com/Spotlight/Huawei-crackdown/US-memory-storage-giant-to-suspend-partnership-with-Huawei2\" target=\"_blank\">suspends</a> its Huawei partnership and stopped shipments to the company after the U.S. blacklisting.</li><li>WDC says Huawei accounts for less than 10% of its overall revenue.</li><li>The companies announced the hard drive and nonvolatile flash storage partnership in April. WDC is also a supplier for Huawei's smartphones.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470540\" data-linked=\"Western Digital cuts ties with Huawei\" data-tweet=\"$WDC - Western Digital cuts ties with Huawei https://seekingalpha.com/news/3470540-western-digital-cuts-ties-huawei?source=tweet\" data-url=\"https://seekingalpha.com/news/3470540-western-digital-cuts-ties-huawei\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470539\" data-ts=\"1560276638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470539-gold-resource-and-westwater-resources-among-energy-materials-gainers-obsidian-energy-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Resource and Westwater Resources among Energy/Materials gainers; Obsidian Energy and SandRidge Permian Trust among losers</a></h4><ul><li><b>Gainers: </b>Gold Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a>) <font color=\"green\">+14%</font>. Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"green\">+11%</font>. PolyOne (NYSE:<a href='https://seekingalpha.com/symbol/POL' title='PolyOne Corporation'>POL</a>) <font color=\"green\">+11%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"green\">+8%</font>. Venator Materials (NYSE:<a href='https://seekingalpha.com/symbol/VNTR' title='Venator Materials PLC'>VNTR</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Obsidian Energy (NYSE:<a href='https://seekingalpha.com/symbol/OBE' title='Obsidian Energy Ltd.'>OBE</a>) <font color=\"red\">-11%</font>. SandRidge Permian Trust (NYSE:<a href='https://seekingalpha.com/symbol/PER' title='SandRidge Permian Trust'>PER</a>) <font color=\"red\">-7%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"red\">-6%</font>. CARBO Ceramics (NYSE:<a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a>) <font color=\"red\">-6%</font>. Hi-Crush (NYSE:<a href='https://seekingalpha.com/symbol/HCR' title='Hi-Crush Inc.'>HCR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470539\" data-linked=\"Gold Resource and Westwater Resources among Energy/Materials gainers; Obsidian Energy and SandRidge Permian Trust among losers\" data-tweet=\"$GORO $WWR $POL - Gold Resource and Westwater Resources among Energy/Materials gainers; Obsidian Energy and SandRidge Permian Trust among losers https://seekingalpha.com/news/3470539-gold-resource-and-westwater-resources-among-energy-materials-gainers-obsidian-energy-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3470539-gold-resource-and-westwater-resources-among-energy-materials-gainers-obsidian-energy-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470537\" data-ts=\"1560276522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNFT\" target=\"_blank\">GNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470537-genfit-defends-elafibranor-after-cymabay-linked-selloff-shares-off-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genfit defends elafibranor after CymaBay-linked selloff; shares off 14%</a></h4><ul><li>In the wake of a <a href=\"https://seekingalpha.com/news/3470433-cymabay-downdraft-snares-genfit-13-percent\" target=\"_blank\">selloff </a>stoked by disappointing results for CymaBay's (<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a> <font color='red'>-45.4%</font>) NASH candidate seladelpar, Genfit SA (<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a> <font color=\"red\">-14.2%</font>) has released a <a href=\"https://www.genfit.com/wp-content/uploads/2019/06/2019.06.11-Note-CBAY-Investors-EN.pdf\" target=\"_blank\">letter </a>to investors aimed at clearing up any \"confusion\" with elafibranor. To wit:</li><li>FDA approval will be based on NASH resolution without worsening of fibrosis via histological examination (evaluating tissue samples with a microscope). By this definition, elafibranor was successful in a Phase 2b study. An ongoing Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02704403?term=genfit&amp;rank=5\" target=\"_blank\">RESOLVE-IT</a>, has the same endpoint. Preliminary data should be available by year-end.</li><li>The reduction in liver fat content, the endpoint in CymaBay's <a href=\"https://seekingalpha.com/news/3470340-cymabay-40-percent-premarket-disappointing-data-nash-candidate-seladelpar\" target=\"_blank\">Phase 2b study</a> that caused the selloff, is not considered a relevant efficacy endpoint by regulators.</li><li>It has also shown beneficial effects on HbA1C, insulin sensitivity and \"bad cholesterol.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3470537\" data-linked=\"Genfit defends elafibranor after CymaBay-linked selloff; shares off 14%\" data-tweet=\"$GNFT $CBAY $CBAY - Genfit defends elafibranor after CymaBay-linked selloff; shares off 14% https://seekingalpha.com/news/3470537-genfit-defends-elafibranor-after-cymabay-linked-selloff-shares-off-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3470537-genfit-defends-elafibranor-after-cymabay-linked-selloff-shares-off-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470536\" data-ts=\"1560276267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470536-uber-ceos-options-repricing-information\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber CEO&#39;s options repricing - The Information</a></h4><ul><li>Speaking at the Economic Club of Washington, Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a> <font color='red'>-0.4%</font>) CEO Dara Khosrowshahi <a href=\"https://www.reuters.com/article/us-uber-ceo/uber-chief-executive-laments-u-s-trade-policy-for-lackluster-ipo-idUSKCN1TC28D?feedType=RSS&amp;feedName=topNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtopNews+%28News+%2F+US+%2F+Top+News%29\" target=\"_blank\">says</a>, \u201cThe timing of our IPO was very much aligned with our president\u2019s tariff wars, the same day. So I think we got caught up a bit in the market swirl. And there\u2019s nothing you can do about that.\u201d</li><li>He says last week's C-suite resignations were \"tough changes but I think are absolutely the right changes for the next three to five years.\"</li><li>Earlier today, <a href=\"https://www.theinformation.com/articles/uber-ceo-shielded-from-stock-drop-by-options-repricing?\" target=\"_blank\">The Information</a> reported on a filing showing Khosrowshahi's options on 750K Uber shares had an exercise price adjustment last month to $33.65/share. The options had a $41.65 exercise price when granted in 2017.</li><li>Uber says the repricing shortens the timeline over which they are granted from to seven years from 10 years, and there was no material change to the grant's total value.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470536\" data-linked=\"Uber CEO&#39;s options repricing - The Information\" data-tweet=\"$UBER - Uber CEO&#39;s options repricing - The Information https://seekingalpha.com/news/3470536-uber-ceos-options-repricing-information?source=tweet\" data-url=\"https://seekingalpha.com/news/3470536-uber-ceos-options-repricing-information\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470621\" data-ts=\"1560275847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470621-europe-steel-industry-likely-past-bottom-arcelormittal-exec-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Europe steel industry likely past bottom, ArcelorMittal exec says</a></h4><ul><li>While it is too early to call a recovery, <a href=\"https://www.bloomberg.com/news/articles/2019-06-10/europe-s-steel-industry-probably-past-bottom-arcelormittal-says\" target=\"_blank\">Europe's steel market may have bottomed out</a> as steel prices in the European Union are starting to climb, Geert van Poelvoorde, ArcelorMittal's (<a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+6.5%</font>) top executive for flat products in Europe, tells Bloomberg.</li><li>Prices for North Europe hot rolled coil rose by \u20ac15/ton to \u20ac480 in the week through June 3, the biggest increase in more than a year, according to Kallanish Commodities - \"far from sufficient,\" with prices still \u20ac50-\u20ac60 below year-ago levels and costs much higher, Poelvoorde says.</li><li>The market may start to recover in this year's Q4 if a rebound in the auto sector materializes and if the European Commission limits low-cost steel imports flooding the continent, van Poelvoorde says.</li><li>ETF: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3470621\" data-linked=\"Europe steel industry likely past bottom, ArcelorMittal exec says\" data-tweet=\"$MT $SLX - Europe steel industry likely past bottom, ArcelorMittal exec says https://seekingalpha.com/news/3470621-europe-steel-industry-likely-past-bottom-arcelormittal-exec-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3470621-europe-steel-industry-likely-past-bottom-arcelormittal-exec-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470532\" data-ts=\"1560275540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTT\" target=\"_blank\">GTT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470532-gtt-deals-lenders-to-add-50m-to-revolving-credit-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GTT deals with lenders to add $50M to revolving credit facility</a></h4><ul>   <li>GTT Communications (<a href=\"http://seekingalpha.com/symbol/GTT\" target=\"_blank\">GTT</a> <font color=\"red\">-3.4%</font>) has an agreement with lenders to <a href=\"https://seekingalpha.com/filing/4528389\" target=\"_blank\">add $50M in new revolving credit commitments</a>.</li>    <li>KeyBank serves as the agent and letter of credit issuer on the deal.</li>    <li>That will boost the revolver to $250M in capacity, relieving some pressure about the company's debt vs. a revenue outlook the company says is improving.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470532\" data-linked=\"GTT deals with lenders to add $50M to revolving credit facility\" data-tweet=\"$GTT - GTT deals with lenders to add $50M to revolving credit facility https://seekingalpha.com/news/3470532-gtt-deals-lenders-to-add-50m-to-revolving-credit-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3470532-gtt-deals-lenders-to-add-50m-to-revolving-credit-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470528\" data-ts=\"1560274692\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470528-national-beverage-responds-to-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage responds to lawsuit</a></h4><ul> <li>National Beverage (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-9.6%</font>) posts a response to a legal action brought against it from a former employee.</li> <li>\"All LaCroix beverages are now produced in cans without BPA liners.  We began converting to BPA-free liners two years ago, and continued as suppliers were able to supply cans.  As of April 2019, all cans produced for LaCroix products were produced without BPA liners. The FDA has stated BPA liners are safe and pose no risk at the trace levels found from its use in can linings of food and beverage products. False statements were made in litigation brought by a former employee seeking to extract a monetary recovery from the company.  We intend to vigorously defend our company and our brands against false claims brought by this disgruntled former employee.\"</li> <li>Shares of FIZZ traded at a 52-week low of $42.54 earlier in today's session, but have tracked higher following the response.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470528\" data-linked=\"National Beverage responds to lawsuit\" data-tweet=\"$FIZZ - National Beverage responds to lawsuit https://seekingalpha.com/news/3470528-national-beverage-responds-to-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3470528-national-beverage-responds-to-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470518\" data-ts=\"1560272409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470518-shiloh-industries-leads-industrial-gainers-u-s-concrete-and-highpower-international-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shiloh Industries leads industrial gainers; U.S. Concrete and Highpower International among losers</a></h4><ul><li><b>Gainers: </b>Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color=\"green\">+11%</font>. Limbach Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMB' title='Limbach Holdings, Inc.'>LMB</a>) <font color=\"green\">+8%</font>. Avalon Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/AWX' title='Avalon Holdings Corporation'>AWX</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>U.S. Concrete (NASDAQ:<a href='https://seekingalpha.com/symbol/USCR' title='U.S. Concrete, Inc.'>USCR</a>) <font color=\"red\">-9%</font>. Mayville Engineering Company (NYSE:<a href='https://seekingalpha.com/symbol/MEC' title='Mayville Engineering Company, Inc.'>MEC</a>) <font color=\"red\">-7%</font>. Summit Materials (NYSE:<a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials, Inc.'>SUM</a>) <font color=\"red\">-7%</font>. Highpower International (NASDAQ:<a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a>) <font color=\"red\">-7%</font>. Concrete Pumping Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BBCP' title='Industrea Acquisition Corp.'>BBCP</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470518\" data-linked=\"Shiloh Industries leads industrial gainers; U.S. Concrete and Highpower International among losers\" data-tweet=\"$SHLO $LMB $AWX - Shiloh Industries leads industrial gainers; U.S. Concrete and Highpower International among losers https://seekingalpha.com/news/3470518-shiloh-industries-leads-industrial-gainers-u-s-concrete-and-highpower-international-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3470518-shiloh-industries-leads-industrial-gainers-u-s-concrete-and-highpower-international-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470516\" data-ts=\"1560272315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470516-financials-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers:</b> Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"green\">+16%</font>. GAIN Capital Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GCAP' title='GAIN Capital Holdings, Inc.'>GCAP</a>) <font color=\"green\">+6%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+6%</font>. Kingstone Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/KINS' title='Kingstone Companies, Inc.'>KINS</a>) <font color=\"green\">+5%</font>. Puyi (NASDAQ:<a href='https://seekingalpha.com/symbol/PUYI' title='Puyi Inc.'>PUYI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> eXp World Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPI' title='eXp World Holdings, Inc.'>EXPI</a>) <font color=\"red\">-7%</font>. Golden Bull (NASDAQ:<a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Limited'>DNJR</a>) <font color=\"red\">-7%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"red\">-7%</font>. Crawford &amp; Company (CRD-B) <font color=\"red\">-6%</font>. eHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470516\" data-linked=\"Financials - Top 5 Gainers / Losers\" data-tweet=\"$OXBR $GCAP $CIFS - Financials - Top 5 Gainers / Losers https://seekingalpha.com/news/3470516-financials-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470516-financials-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470511\" data-ts=\"1560271265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470511-healthcare-tops-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare tops midday movers</a></h4><ul><li><strong>Gainers: </strong>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"green\">+60%</font>. ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+40%</font>. TORM (NASDAQ:<a href='https://seekingalpha.com/symbol/TRMD' title='TORM plc'>TRMD</a>) <font color=\"green\">+20%</font>. Rekor Systems, Inc. (REKR) <font color=\"green\">+17%</font>. Enzo Biochem, Inc. (NYSE:<a href='https://seekingalpha.com/symbol/ENZ' title='Enzo Biochem, Inc.'>ENZ</a>) <font color=\"green\">+17%</font>. Oxbridge Re Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a>) <font color=\"green\">+16%</font>. Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"green\">+16%</font>. Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+16%</font>. Hemispherx Biopharma (NYSEMKT:<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a>) <font color=\"green\">+14%</font>. Gold Resource Corporation (NYSEMKT:<a href='https://seekingalpha.com/symbol/GORO' title='Gold Resource Corporation'>GORO</a>) <font color=\"green\">+14%</font>.</li> <li><strong>Losers: </strong>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-46%</font>. Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-30%</font>. Urban One (NASDAQ:<a href='https://seekingalpha.com/symbol/UONE' title='Urban One, Inc.'>UONE</a>) <font color=\"red\">-30%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-25%</font>. TherapeuticsMD (NASDAQ:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD, Inc.'>TXMD</a>) <font color=\"red\">-21%</font>. Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"red\">-20%</font>. The Lovesac Company (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"red\">-16%</font>. Genfit SA (NASDAQ:<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a>) <font color=\"red\">-15%</font>. Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"red\">-13%</font>. Performance Shipping (NASDAQ:<a href='https://seekingalpha.com/symbol/DCIX' title='Performance Shipping Inc.'>DCIX</a>) <font color=\"red\">-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470511\" data-linked=\"Healthcare tops midday movers\" data-tweet=\"$JAGX $HEPA $TRMD - Healthcare tops midday movers https://seekingalpha.com/news/3470511-healthcare-tops-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470511-healthcare-tops-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470510\" data-ts=\"1560271231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470510-new-york-and-nine-ags-sue-to-block-sprint-t-mobile-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New York and nine other AGs sue to block Sprint/T-Mobile merger</a></h4><ul>   <li>New York's attorney general confirms that the state is <a href=\"http://www.marylandattorneygeneral.gov/News%20Documents/061119_Complaint_9_cv_5434.pdf\" target=\"_blank\">suing to block</a> the $26B merger of Sprint and T-Mobile along with nine other attorneys general.</li>    <li>Named as plaintiffs along with the State of New York are California, Colorado, Connecticut, Maryland, Michigan, Mississippi, Virginia, Wisconsin and the District of Columbia.</li>    <li>They're suing Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>), T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) and their parents SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group Corp.'>OTCPK:SFTBY</a>) and Deutsche Telekom (<a href='https://seekingalpha.com/symbol/DTEGY' title='Deutsche Telekom AG'>OTCQX:DTEGY</a>).</li>    <li>\"If the merger is consummated, it will cause substantial harm to consumers in the Southern District of New York and across the United States,\" the complaint reads.</li>    <li>Current action: Sprint <font color=\"red\">-5.3%</font>; T-Mobile <font color=\"red\">-1.4%</font>; SoftBank <font color=\"red\">-1.7%</font>; Deutsche Telekom flat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470510\" data-linked=\"New York and nine other AGs sue to block Sprint/T-Mobile merger\" data-tweet=\"$S $TMUS $SFTBY - New York and nine other AGs sue to block Sprint/T-Mobile merger https://seekingalpha.com/news/3470510-new-york-and-nine-ags-sue-to-block-sprint-t-mobile-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3470510-new-york-and-nine-ags-sue-to-block-sprint-t-mobile-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>84&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470508\" data-ts=\"1560271072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENZ\" target=\"_blank\">ENZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470508-enzo-biochem-up-17-after-q3-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enzo Biochem up 17% after Q3 beat</a></h4><ul><li>Thinly traded micro cap Enzo Biochem (<a href='https://seekingalpha.com/symbol/ENZ' title='Enzo Biochem, Inc.'>ENZ</a> <font color=\"green\">+16.5%</font>) is up on average volume following its <a href=\"https://seekingalpha.com/pr/17539774-enzo-biochem-reports-fiscal-third-quarter-nine-months-operating-results\" target=\"_blank\">Q3 results</a> released after the close yesterday.</li><li>Revenues were down 22% to $19.7M, but net income was up 738% to $22.3M due mostly to settlements from two patent infringement cases, one in New York and one in Delaware.</li><li>EPS was $0.47 (+783%). Non-GAAP EPS was ($0.14) (-33%).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3470255-enzo-biochem-eps-beats-0_01-beats-revenue\" target=\"_blank\">Enzo Biochem EPS beats by $0.01, beats on revenue</a> (June 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3470508\" data-linked=\"Enzo Biochem up 17% after Q3 beat\" data-tweet=\"$ENZ - Enzo Biochem up 17% after Q3 beat https://seekingalpha.com/news/3470508-enzo-biochem-up-17-after-q3-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3470508-enzo-biochem-up-17-after-q3-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470506\" data-ts=\"1560270684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WKHS\" target=\"_blank\">WKHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470506-workhorse-drops-after-detailing-private-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workhorse drops after detailing private offering</a></h4><ul><li>Workhorse Group (<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='red'>-11.2%</font>) says it entered into subscription agreements with a group of investors for a $25M private offering</li><li>Under the terms of the agreements, the investors acquired shares of Series B preferred stock and warrants to purchase common stock.  The Series B preferred stock is not convertible, but the holders are entitled to annual dividends payable in shares of common stock.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17539178-workhorse-group-secures-25-million-financing\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3470506\" data-linked=\"Workhorse drops after detailing private offering\" data-tweet=\"$WKHS - Workhorse drops after detailing private offering https://seekingalpha.com/news/3470506-workhorse-drops-after-detailing-private-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3470506-workhorse-drops-after-detailing-private-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470505\" data-ts=\"1560270612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470505-turtle-beachplus-9-on-insider-purchases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turtle Beach +9% on insider purchases</a></h4><ul><li>Turtle Beach (NASDAQ:<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a>) <font color=\"green\">+9.3% </font>on regulatory filings disclosing that CEO Juergen Stark <a href=\"https://seekingalpha.com/filing/4527936\" target=\"_blank\">purchased</a> $102,690 worth of shares.</li><li>Director Andrew Wolfe <a href=\"https://seekingalpha.com/filing/4527935\" target=\"_blank\">acquired</a> 10,000 shares at an average price of $9.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470505\" data-linked=\"Turtle Beach +9% on insider purchases\" data-tweet=\"$HEAR - Turtle Beach +9% on insider purchases https://seekingalpha.com/news/3470505-turtle-beachplus-9-on-insider-purchases?source=tweet\" data-url=\"https://seekingalpha.com/news/3470505-turtle-beachplus-9-on-insider-purchases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470502\" data-ts=\"1560270301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEB\" target=\"_blank\">HEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470502-hemispherx-bio-up-18-after-reverse-stock-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hemispherx Bio up 18% after reverse stock split</a></h4><ul><li>Hemispherx Biopharma (<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc.'>HEB</a> <font color=\"green\">+17.7%</font>) is up on increased volume following its <a href=\"https://seekingalpha.com/pr/17530511-hemispherx-biopharma-stockholders-approve-reverse-stock-split\" target=\"_blank\">1:44 reverse stock split</a>. Post-split trading started today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470502\" data-linked=\"Hemispherx Bio up 18% after reverse stock split\" data-tweet=\"$HEB $AIM - Hemispherx Bio up 18% after reverse stock split https://seekingalpha.com/news/3470502-hemispherx-bio-up-18-after-reverse-stock-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3470502-hemispherx-bio-up-18-after-reverse-stock-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470501\" data-ts=\"1560270239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470501-blackberry-u-s-government-solution-named-fedramp-ready\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry U.S. government solution named FedRAMP Ready</a></h4><ul>   <li>BlackBerry (<a href=\"http://seekingalpha.com/symbol/BB\" target=\"_blank\">BB</a> <font color=\"green\">+5.2%</font>) today says its U.S.-targeted Government Mobility Suite has achieved <a href=\"https://seekingalpha.com/pr/17540661-blackberrys-government-mobility-suite-achieves-fedramp-ready-designation\" target=\"_blank\">FedRAMP Ready status</a>, setting up for closer ties with the American government.</li>    <li>Along with that designation, the offering is listed on the Federal Risk and Authorization Management Program's Marketplace.</li>    <li>FedRAMP monitoring of the Government Mobility Suite will be provided out of BlackBerry's recently announced facility in Washington, D.C.</li>    <li>The suite offers IT administrators a single, integrated view of users, devices, applications, and policies across multi-OS endpoints and ownership models.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470501\" data-linked=\"BlackBerry U.S. government solution named FedRAMP Ready\" data-tweet=\"$BB - BlackBerry U.S. government solution named FedRAMP Ready https://seekingalpha.com/news/3470501-blackberry-u-s-government-solution-named-fedramp-ready?source=tweet\" data-url=\"https://seekingalpha.com/news/3470501-blackberry-u-s-government-solution-named-fedramp-ready\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470500\" data-ts=\"1560270031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470500-national-beverageminus-8-on-report-of-new-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage -8% on report of new lawsuit</a></h4><ul> <li>National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) is <font color=\"red\">down 7.67%</font> in midday trading after the company and Caporella were <a href=\"https://www.businessinsider.com/lacroix-lawsuit-claims-executives-sparred-over-bpa-free-claims-2019-6\" target=\"_blank\">sued</a> by a former exec.</li><li>The suit alleges that a LaCroix exec was fired for raising issues with claims that sparkling water products were free of Bisphenol A.</li> <li>Shares of FIZZ are down 39% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3470500\" data-linked=\"National Beverage -8% on report of new lawsuit\" data-tweet=\"$FIZZ - National Beverage -8% on report of new lawsuit https://seekingalpha.com/news/3470500-national-beverageminus-8-on-report-of-new-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3470500-national-beverageminus-8-on-report-of-new-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470498\" data-ts=\"1560269987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STT\" target=\"_blank\">STT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470498-state-streetminus-4_2-on-dimmer-q2-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">State Street -4.2% on dimmer Q2 outlook</a></h4><ul><li>State Street (NYSE:<a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a>) <font color=\"red\">slumps 4.2%</font> after CFO Eric Aboaf said the bank's fee revenue is likely to fall 1%-2% Q/Q in Q2 on \"lower FX volatility and lighter client volumes.</li><li>Bloomberg reports comments made at an industry conference.</li><li>Sees Q2 net interest income declining 8% Q/Q as a result of \"significant turn in the interest-rate evironment.</li><li>In April Aboaf had expected fee revenue flat to +1% in Q2 and NII falling as much as 2%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470498\" data-linked=\"State Street -4.2% on dimmer Q2 outlook\" data-tweet=\"$STT - State Street -4.2% on dimmer Q2 outlook https://seekingalpha.com/news/3470498-state-streetminus-4_2-on-dimmer-q2-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3470498-state-streetminus-4_2-on-dimmer-q2-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470496\" data-ts=\"1560269761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLR\" target=\"_blank\">DLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470496-mc-digital-realty-opens-new-data-center-in-osaka\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MC Digital Realty opens new data center in Osaka</a></h4><ul>   <li>MC Digital Realty -- the 50/50 joint venture between Mitsubishi Corp. and Digital Realty (<a href=\"http://seekingalpha.com/symbol/DLR\" target=\"_blank\">DLR</a> <font color=\"green\">+1.6%</font>) -- has opened a new <a href=\"https://seekingalpha.com/pr/17539983-mc-digital-realty-announces-grand-opening-new-data-center-osaka\" target=\"_blank\">data center in Osaka, Japan</a>.</li>    <li>The KIX11 facility is the second on the company's Osaka connected campus.</li>    <li>It's anchored by a multi-megawatt, multiyear deal with a leading global cloud service provider.</li>    <li>The new four-story facility spans more than 23,000 square meters and delivers up to 28 megawatts of total capacity.</li>    <li>Along with two data centers in the Tokyo metro, that brings MC Digital Realty's portfolio to four data centers in Japan.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470496\" data-linked=\"MC Digital Realty opens new data center in Osaka\" data-tweet=\"$DLR - MC Digital Realty opens new data center in Osaka https://seekingalpha.com/news/3470496-mc-digital-realty-opens-new-data-center-in-osaka?source=tweet\" data-url=\"https://seekingalpha.com/news/3470496-mc-digital-realty-opens-new-data-center-in-osaka\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470495\" data-ts=\"1560269750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470495-boeings-may-ytd-deliveries-tumble-amid-737-max-grounding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing&#39;s May, YTD deliveries tumble amid 737 MAX grounding</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"red\">-1.5%</font>) reports <a href=\"https://finance.yahoo.com/news/boeing-may-deliveries-fall-56-153047400.html\" target=\"_blank\">May deliveries fell 56%</a> Y/Y to 30 planes from 68 in the year-ago month, as deliveries for its top-selling 737 MAX jets remained halted.</li><li>Net orders YTD remained in negative territory, with a total of minus 125 net orders.</li><li>Rival Airbus delivered 81 aircraft in May, up 59% Y/Y, and 313 in the January-May period, a 40% increase.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470495\" data-linked=\"Boeing&#39;s May, YTD deliveries tumble amid 737 MAX grounding\" data-tweet=\"$BA - Boeing&#39;s May, YTD deliveries tumble amid 737 MAX grounding https://seekingalpha.com/news/3470495-boeings-may-ytd-deliveries-tumble-amid-737-max-grounding?source=tweet\" data-url=\"https://seekingalpha.com/news/3470495-boeings-may-ytd-deliveries-tumble-amid-737-max-grounding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470494\" data-ts=\"1560269710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470494-green-stream-holdings-declares-special-common-stock-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Green Stream Holdings declares a special common stock dividend</a></h4><ul><li>Green Stream Holdings (GSFI <font color=\"green\">+8.9%</font>) has approved a special stock dividend to Green Stream Holdings stockholders of one share of restricted common stock for every 100 shares of common stock presently owned.</li><li>Payable July 30; for shareholders of record June 14.</li><li>No fractional shares of common stock will be distributed. Instead, Green Stream stockholders will receive a number rounded to the next highest number.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470494\" data-linked=\"Green Stream Holdings declares a special common stock dividend\" data-tweet=\"Green Stream Holdings declares a special common stock dividend https://seekingalpha.com/news/3470494-green-stream-holdings-declares-special-common-stock-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3470494-green-stream-holdings-declares-special-common-stock-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470492\" data-ts=\"1560269486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONOV\" target=\"_blank\">ONOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470492-new-chief-bionovelus-shares-up-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief at BioNovelus; shares up 19%</a></h4><ul><li>Thinly traded nano cap BioNovelus (<a href='https://seekingalpha.com/symbol/ONOV' title='BioNovelus Inc.'>OTCPK:ONOV</a> <font color=\"green\">+18.9%</font>) <a href=\"https://seekingalpha.com/pr/17540825-bionovelus-inc-announces-acquisition-bayberry-acquisition-corp-hires-mark-fuller-new\" target=\"_blank\">appoints</a> Mark Fuller as CEO. Previously he was CEO at Techshot Lighting, LLC.</li><li>The company also reports that it has finalized its takeover of Bayberry Acquisition Corp.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470492\" data-linked=\"New chief at BioNovelus; shares up 19%\" data-tweet=\"$ONOV - New chief at BioNovelus; shares up 19% https://seekingalpha.com/news/3470492-new-chief-bionovelus-shares-up-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3470492-new-chief-bionovelus-shares-up-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470491\" data-ts=\"1560269182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470491-ziopharm-up-3-on-fda-sign-off-on-study-involving-sleeping-beauty-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm up 3% on  FDA sign-off on study involving Sleeping Beauty platform</a></h4><ul><li>Ziopharm Oncology (<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color=\"green\">+3.3%</font>) perks up on average volume in reaction to its <a href=\"https://seekingalpha.com/pr/17540427-ziopharm-oncology-announces-fda-clearance-ind-sleeping-beauty-tcr-t-cell-therapy-trial-nci\" target=\"_blank\">announcement </a>that the FDA has signed off on a National Cancer Institute-sponsored study evaluating T-cell receptor &#40;TCR&#41; T-cell therapy using the company's <em>Sleeping Beauty</em> platform for the treatment of solid tumors.</li><li><em><a href=\"https://ziopharm.com/t-cell-therapy/overview/\" target=\"_blank\">Sleeping Beauty</a></em> is a non-viral gene transfer technology that the NCI will use to generate neoantigen-specific T cells.</li><li>The company will host a conference call on Wednesday, June 12, at 8:30 am ET to discuss its non-viral TCR-T program.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470491\" data-linked=\"Ziopharm up 3% on  FDA sign-off on study involving Sleeping Beauty platform\" data-tweet=\"$ZIOP - Ziopharm up 3% on FDA sign-off on study involving Sleeping Beauty platform https://seekingalpha.com/news/3470491-ziopharm-up-3-on-fda-sign-off-on-study-involving-sleeping-beauty-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3470491-ziopharm-up-3-on-fda-sign-off-on-study-involving-sleeping-beauty-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470488\" data-ts=\"1560268899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470488-davidstea-and-adient-among-consumer-gainers-beyond-meat-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DAVIDsTEA and Adient among consumer gainers; Beyond Meat leads the losers</a></h4><ul><li><b>Gainers: </b>DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"green\">+12%</font>. BRP (NASDAQ:<a href='https://seekingalpha.com/symbol/DOOO' title='BRP Inc.'>DOOO</a>) <font color=\"green\">+6%</font>. Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) <font color=\"green\">+6%</font>. Limoneira Company (NASDAQ:<a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira Company'>LMNR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"red\">-21%</font>.The Lovesac Company (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"red\">-16%</font>. Workhorse Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>) <font color=\"red\">-8%</font>. National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470488\" data-linked=\"DAVIDsTEA and Adient among consumer gainers; Beyond Meat leads the losers\" data-tweet=\"$DTEA $DOOO $ADNT - DAVIDsTEA and Adient among consumer gainers; Beyond Meat leads the losers https://seekingalpha.com/news/3470488-davidstea-and-adient-among-consumer-gainers-beyond-meat-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470488-davidstea-and-adient-among-consumer-gainers-beyond-meat-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470486\" data-ts=\"1560268737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470486-chemours-ceo-vergnano-bought-1m-in-company-stock-yesterday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemours CEO Vergnano bought $1M in company stock yesterday</a></h4><ul><li>Chemours (<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a> <font color='green'>+4.4%</font>) shoots higher following a disclosure that President and CEO Mark Vergnano <a href=\"https://www.sec.gov/Archives/edgar/data/1627223/000156459019022127/cc-8k_20190610.htm\" target=\"_blank\">bought 44K shares</a> of CC on June 10, totaling more than $1M.</li><li>Following the purchase, Vergnano owns a total of 690,254 CC common shares.</li><li>CC shares fell 41% last month after reporting <a href=\"https://seekingalpha.com/news/3458353-chemours-misses-0_31-misses-revenue\" target=\"_blank\">disappointing Q1 results</a>, including Y/Y revenue declines in all three of the company's business segments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470486\" data-linked=\"Chemours CEO Vergnano bought $1M in company stock yesterday\" data-tweet=\"$CC - Chemours CEO Vergnano bought $1M in company stock yesterday https://seekingalpha.com/news/3470486-chemours-ceo-vergnano-bought-1m-in-company-stock-yesterday?source=tweet\" data-url=\"https://seekingalpha.com/news/3470486-chemours-ceo-vergnano-bought-1m-in-company-stock-yesterday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470484\" data-ts=\"1560268624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470484-thor-industriesminus-5-baml-pitches-bear-case-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thor Industries -5% as BAML pitches bear case again</a></h4><ul> <li>Bank of America Merrill Lynch ratchets down expectations on Thor Industries (<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color=\"red\">-4.9%</font>) again.</li> <li>The firm now sees FY19 EPS of $5.47 vs. $5.85 prior, FY20 EPS of $7.20 vs. $7.65 prior and FY21 EPS of $8.25 vs. $8.40 prior. following a challenging FY3Q.</li> <li>BAML also reduces its price objective on Thor to $58 from $62 as it warns on industry supply/demand headwinds integration risk from the EHG deal.</li> <li>BAML is an outlier on Thor with an Underperform rating vs. the average <a href=\"https://seekingalpha.com/symbol/THO/ratings/sell-side-ratings\" target=\"_blank\">sell-side rating</a> of Outperform and SA authors also in the <a href=\"https://seekingalpha.com/symbol/THO/ratings/author-ratings#filter=all\" target=\"_blank\">bull</a> camp.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470484\" data-linked=\"Thor Industries -5% as BAML pitches bear case again\" data-tweet=\"$THO - Thor Industries -5% as BAML pitches bear case again https://seekingalpha.com/news/3470484-thor-industriesminus-5-baml-pitches-bear-case-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3470484-thor-industriesminus-5-baml-pitches-bear-case-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470477\" data-ts=\"1560267674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAN\" target=\"_blank\">PLAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470477-anaplanminus-3_1-on-7_1m-insider-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anaplan -3.1% on $7.1M insider sale</a></h4><ul><li>Anaplan (NYSE:<a href='https://seekingalpha.com/symbol/PLAN' title='Anaplan, Inc.'>PLAN</a>) board member Ravi Mohan sold 149,257 shares at an average price of $47.80, according to a <a href=\"https://investors.anaplan.com/financials/sec-filings/default.aspx\" target=\"_blank\">regulatory filing</a>.</li><li>PLAN's IPO lockup period expired on April 10.</li><li>Anaplan shares are <font color=\"red\">down 3.1%</font> to $46.98.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470477\" data-linked=\"Anaplan -3.1% on $7.1M insider sale\" data-tweet=\"$PLAN - Anaplan -3.1% on $7.1M insider sale https://seekingalpha.com/news/3470477-anaplanminus-3_1-on-7_1m-insider-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3470477-anaplanminus-3_1-on-7_1m-insider-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470476\" data-ts=\"1560267583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470476-adamis-amends-u-s-application-for-higher-dose-naloxone-hopes-for-speedy-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval</a></h4><ul><li>Based on FDA feedback, Adamis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a> <font color=\"red\">-4.5%</font>) has <a href=\"https://seekingalpha.com/pr/17540805-adamis-pharmaceuticals-provides-update-higher-dose-naloxone-injection-product\" target=\"_blank\">removed </a>kaléo's <a href=\"https://www.evzio.com/patient/\" target=\"_blank\">EVZIO </a>(naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug &#40;RLD&#41; in its marketing application seeking approval for its higher dose naloxone injection product for the emergency treatment of opioid overdose. It has also withdrawn the associated Paragraph IV certification (enables a generic drug maker to challenge an existing patent in court after notifying the patent holder).</li><li>The company hopes that the agency will now approve the application in a timely fashion since the sole remaining RLD is Narcan injectable which has no Orange Book-listed patents. The agency's <a href=\"https://seekingalpha.com/news/3443211-fda-accepts-adamis-pharmas-application-higher-dose-naloxone-shares-2-percent-premarket\" target=\"_blank\">action date</a> is October 31.</li><li>Adamis is being sued for patent infringement by kaléo but believes that its higher dose formulation does not infringe, adding that it will \"continue to vigorously defend its naloxone injection product\" against any infringement allegations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470476\" data-linked=\"Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval\" data-tweet=\"$ADMP - Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval https://seekingalpha.com/news/3470476-adamis-amends-u-s-application-for-higher-dose-naloxone-hopes-for-speedy-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3470476-adamis-amends-u-s-application-for-higher-dose-naloxone-hopes-for-speedy-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470474\" data-ts=\"1560267447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470474-albemarle-says-will-not-participate-in-lme-lithium-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle says will not participate in LME lithium contract</a></h4><ul><li>The London Metal Exchange's plans to launch a new contract for lithium are deprived of a key source of pricing data as top producer Albemarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='green'>+2.4%</font>) says it <a href=\"https://www.reuters.com/article/lithium-electric-lme/update-1-albemarle-says-will-not-participate-in-lme-lithium-contract-idUSL2N23I0NQ\" target=\"_blank\">will not participate</a> in the effort.</li><li>The contract would go against the company's view that lithium is a specialty chemical, not a commodity, David Ryan, ALB's head of corporate strategy and investor relations, told a lithium industry conference today in Santiago, Chile.</li><li>Ryan spoke on a panel presentation alongside executives from rivals SQM (<a href='https://seekingalpha.com/symbol/SQM' title='Sociedad Química y Minera de Chile S.A.'>SQM</a> <font color='green'>+3.6%</font>) and Tianqi Lithium, who agreed that lithium is not a true commodity but stopped short of saying their companies would not work with the LME.</li><li>Unlike for copper or other metals used to make electric cars, no traded price exists for lithium, leaving the industry's investors and executives without a full sense of the global market.</li><li>ETF: <a href='https://seekingalpha.com/symbol/LIT' title='Global X Lithium ETF'>LIT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3470474\" data-linked=\"Albemarle says will not participate in LME lithium contract\" data-tweet=\"$ALB $SQM $LIT - Albemarle says will not participate in LME lithium contract https://seekingalpha.com/news/3470474-albemarle-says-will-not-participate-in-lme-lithium-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3470474-albemarle-says-will-not-participate-in-lme-lithium-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470463\" data-ts=\"1560265320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470463-zynerba-pharmaceuticals-and-sesen-bio-among-healthcare-gainers-cymabay-therapeutics-leads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba Pharmaceuticals and Sesen Bio among healthcare gainers; CymaBay Therapeutics leads the losers</a></h4><ul><li><b>Gainers: </b>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+62%</font>. Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"green\">+41%</font>. Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+19%</font>. Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"green\">+14%</font>. Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-43%</font>. Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-34%</font>. NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"red\">-19%</font>. Genfit (NASDAQ:<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a>) <font color=\"red\">-14%</font>. TherapeuticsMD (NASDAQ:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD, Inc.'>TXMD</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470463\" data-linked=\"Zynerba Pharmaceuticals and Sesen Bio among healthcare gainers; CymaBay Therapeutics leads the losers\" data-tweet=\"$HEPA $JAGX $ZYNE - Zynerba Pharmaceuticals and Sesen Bio among healthcare gainers; CymaBay Therapeutics leads the losers https://seekingalpha.com/news/3470463-zynerba-pharmaceuticals-and-sesen-bio-among-healthcare-gainers-cymabay-therapeutics-leads?source=tweet\" data-url=\"https://seekingalpha.com/news/3470463-zynerba-pharmaceuticals-and-sesen-bio-among-healthcare-gainers-cymabay-therapeutics-leads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470461\" data-ts=\"1560264649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JW.A\" target=\"_blank\">JW.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470461-wiley-sonsplus-6_7-cost-control-boosts-profits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wiley &amp; Sons +6.7% as cost control boosts profits</a></h4><ul>   <li>Textbook specialist John Wiley &amp; Sons (NYSE:<a href='https://seekingalpha.com/symbol/JW.A' title='John Wiley & Sons, Inc.'>JW.A</a>) is <font color=\"green\">6.7% higher</font> after today's earnings topper, where profit growth outpaced revenue gains amid slower expense growth.</li>    <li>Revenue rose about 3% on a GAAP and adjusted basis, but operating income of $80M was up 10% (up 17% excluding foreign exchange effects and the Learning House acquisition) and EPS rose to $1.10, up 19% (or up 26% on an adjusted basis).</li>    <li>\u201cWe achieved our targets for revenue and earnings and are seeing good growth in strategic areas such as Research Open Access publishing, Education Services, Test Preparation and Certification, and corporate training,\" says CEO Brian Napack.</li>    <li>It's guiding to fiscal 2020 revenue of $1.84B-$1.87B, with a 2022 target of about $2B. It also sees EBITDA of $360M-$375M (down from fiscal 2019's $388M) and EPS of $2.45-$2.55 (down from 2019's $2.96), along with free cash flow of $210M-$230M.</li>    <li>Its fiscal 2022 target for EBITDA of $440M, and for EPS it's about $3.50.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3470361-john-wiley-and-sons-eps-beats-0_02-beats-revenue\" target=\"_blank\">John Wiley &amp; Sons EPS beats by $0.02, beats on revenue</a> (Jun. 11 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17540326-wiley-reports-fourth-quarter-fiscal-year-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3470461\" data-linked=\"Wiley &amp; Sons +6.7% as cost control boosts profits\" data-tweet=\"$JW.A $JW.B - Wiley &amp; Sons +6.7% as cost control boosts profits https://seekingalpha.com/news/3470461-wiley-sonsplus-6_7-cost-control-boosts-profits?source=tweet\" data-url=\"https://seekingalpha.com/news/3470461-wiley-sonsplus-6_7-cost-control-boosts-profits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470453\" data-ts=\"1560264302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGX\" target=\"_blank\">AGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470453-argan-down-6-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argan down 6% post Q1 results</a></h4><ul><li>Argan (<a href='https://seekingalpha.com/symbol/AGX' title='Argan, Inc.'>AGX</a> <font color=\"red\">-6.2%</font>) reported Q1 revenues decline of 65% Y/Y to $49.54M, reflecting Gemma Power Systems substantial completion on four gas-fired power plant projects during the year ended January 31, 2019 and concluded activities on a fifth gas-fired power plant early in the first quarter.</li><li>The Roberts Company and Atlantic Project Company contributed 75% of consolidated revenues for the quarter.</li><li>Q1 Gross margin was -42.4%, compared to 10.9% a year ago, due to the limited revenues during the quarter and the loss project at Atlantic Project Company.</li><li>Company reports operating loss of $32.87M, compared to $5.81M profit a year ago.</li><li>EBITDA loss was $29.19M, compared to $8.15M last year.</li><li>Project backlog was $1.09B (-0.1% Y/Y); Recently GPS entered into a contract to build the 625 MW Harrison County Power Station, a natural gas-fired power plant, in West Virginia. Including this new contract received subsequent to the end of the quarter, company\u2019s project backlog exceeds $1.4B.</li><li>Company has Cash, cash equivalents and short-term investments of $255.76M as of April 30, 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3470253-argan-eps-1_87\" target=\"_blank\">Argan EPS of -$1.87</a> (June 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3470453\" data-linked=\"Argan down 6% post Q1 results\" data-tweet=\"$AGX - Argan down 6% post Q1 results https://seekingalpha.com/news/3470453-argan-down-6-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3470453-argan-down-6-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470444\" data-ts=\"1560263133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470444-grubhubplus-7_5-on-amazon-restaurants-closure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub +7.5% on Amazon Restaurants closure</a></h4><ul><li>GrubHub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='Grubhub Inc.'>GRUB</a>)<font color=\"green\"> gains 7.5%</font> after a <a href=\"https://www.geekwire.com/2019/amazon-shut-amazon-restaurants-business-u-s/\" target=\"_blank\"><em>GeekWire</em></a> report that Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+1.1%</font>) will shut down its Amazon Restaurants delivery service on June 24.</li><li>Amazon will shutter its workplace lunch delivery service Daily Dish on June 14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470444\" data-linked=\"GrubHub +7.5% on Amazon Restaurants closure\" data-tweet=\"$GRUB $AMZN - GrubHub +7.5% on Amazon Restaurants closure https://seekingalpha.com/news/3470444-grubhubplus-7_5-on-amazon-restaurants-closure?source=tweet\" data-url=\"https://seekingalpha.com/news/3470444-grubhubplus-7_5-on-amazon-restaurants-closure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470443\" data-ts=\"1560262951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAT\" target=\"_blank\">AAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470443-american-assets-trust-enters-agreement-to-acquire-la-jolla-commons\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Assets Trust enters into agreement to acquire La Jolla Commons</a></h4><ul><li>American Assets Trust (<a href='https://seekingalpha.com/symbol/AAT' title='American Assets Trust, Inc.'>AAT</a> <font color='red'>-3.4%</font>) has <a href=\"https://seekingalpha.com/pr/17539710-american-assets-trust-inc-enters-agreement-acquire-la-jolla-commons-san-diego-california\" target=\"_blank\">entered into an agreement</a> to acquire La Jolla Commons, consisting of two trophy office towers, an entitled development parcel and two parking structures, located in the preeminent University Town Center submarket of San Diego, California.</li><li>The purchase price is $525M (less a seller credit of ~$11.5M), is expected to be paid with a combination of cash on hand and Company\u2019s existing credit facility.</li><li>The acquisition is subject to customary closing conditions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470443\" data-linked=\"American Assets Trust enters into agreement to acquire La Jolla Commons\" data-tweet=\"$AAT - American Assets Trust enters into agreement to acquire La Jolla Commons https://seekingalpha.com/news/3470443-american-assets-trust-enters-agreement-to-acquire-la-jolla-commons?source=tweet\" data-url=\"https://seekingalpha.com/news/3470443-american-assets-trust-enters-agreement-to-acquire-la-jolla-commons\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470442\" data-ts=\"1560262548\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARW\" target=\"_blank\">ARW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470442-arrowplus-2-on-deutsches-bullish-return\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrow +2% on Deutsche&#39;s bullish return</a></h4><ul><li>Deutsche Bank reinstates Arrow Electronics (NYSE:<a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics, Inc.'>ARW</a>) with a Buy rating with a PT of $83.</li><li>Last month, Arrow <a href=\"https://seekingalpha.com/news/3457940-arrow-electronics-misses-0_06-beats-revenue\" target=\"_blank\">reported</a> Q1 results that beat revenue estimates and missed on EPS.</li><li>Arrow shares are<font color=\"green\"> up 2.1%</font> to $69.92.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470442\" data-linked=\"Arrow +2% on Deutsche&#39;s bullish return\" data-tweet=\"$ARW - Arrow +2% on Deutsche&#39;s bullish return https://seekingalpha.com/news/3470442-arrowplus-2-on-deutsches-bullish-return?source=tweet\" data-url=\"https://seekingalpha.com/news/3470442-arrowplus-2-on-deutsches-bullish-return\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470437\" data-ts=\"1560262267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470437-sprint-t-mobile-drop-on-report-state-ags-to-sue-to-block-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint, T-Mobile drop on report state AGs to sue to block merger</a></h4><ul>   <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) has <font color=\"red\">dropped 2.2%</font>, and T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) has dropped to a <font color=\"red\">0.7% loss</font>, as Reuters reports that at least 10 state attorneys general are <a href=\"https://www.oann.com/exclusive-u-s-state-ags-prepare-lawsuit-to-stop-sprint-and-t-mobile-merger/\" target=\"_blank\">preparing to sue to stop</a> the wireless carriers' proposed $26B merger.</li>    <li>That suit could come as soon as today, Reuters says.</li>    <li>The New York State attorney general has the lead in the suit, according to the report, and will be holding a news conference this afternoon.</li>   <li>That comes alongside a Fox Business report that a final DOJ decision on the merger <a href=\"https://www.foxbusiness.com/media/makan-delrahim-ajit-pai-meet-friday-to-discuss-t-mobile-sprint-deal-as-doj-decision-looms\" target=\"_blank\">could come this week</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470437\" data-linked=\"Sprint, T-Mobile drop on report state AGs to sue to block merger\" data-tweet=\"$S $TMUS $SFTBF - Sprint, T-Mobile drop on report state AGs to sue to block merger https://seekingalpha.com/news/3470437-sprint-t-mobile-drop-on-report-state-ags-to-sue-to-block-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3470437-sprint-t-mobile-drop-on-report-state-ags-to-sue-to-block-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470433\" data-ts=\"1560261515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNFT\" target=\"_blank\">GNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470433-cymabay-downdraft-snares-genfit-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay downdraft snares Genfit, down 13%</a></h4><ul><li>The <a href=\"https://seekingalpha.com/news/3470340-cymabay-40-percent-premarket-disappointing-data-nash-candidate-seladelpar\" target=\"_blank\">seladelpar-stoked selloff</a> in CymaBay Therapeutics has engulfed fellow NASH player Genfit SA (<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a> <font color=\"red\">-13.3%</font>).</li><li>Seladelpar activates the peroxisome proliferator-activated receptor δ (PPARδ), expressed in a range of liver cells, which plays a key role in regulating genes involved in bile acid synthesis, inflammation, fibrosis and lipid metabolism.</li><li>Genfit's lead drug is elafibranor, a PPAR alpha/delta agonist.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470433\" data-linked=\"CymaBay downdraft snares Genfit, down 13%\" data-tweet=\"$GNFT - CymaBay downdraft snares Genfit, down 13% https://seekingalpha.com/news/3470433-cymabay-downdraft-snares-genfit-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3470433-cymabay-downdraft-snares-genfit-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470430\" data-ts=\"1560261088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXPI\" target=\"_blank\">NXPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470430-nxpplus-1_4-on-cash-tender-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NXP +1.4% on cash tender offer</a></h4><ul><li>NXP Semi (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors N.V.'>NXPI</a>) <a href=\"https://seekingalpha.com/pr/17540914-nxp-commences-tender-offer-4_125-percent-senior-notes-due-2020\" target=\"_blank\">announces </a>an offer for any and all outstanding 4.125% Senior Notes due 2020.</li><li>The offer will expire at 5 PM ET on June 17 unless extended or terminated.</li><li>NXPI shares are <font color=\"green\">up 1.4%</font> to $96.72.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470430\" data-linked=\"NXP +1.4% on cash tender offer\" data-tweet=\"$NXPI - NXP +1.4% on cash tender offer https://seekingalpha.com/news/3470430-nxpplus-1_4-on-cash-tender-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3470430-nxpplus-1_4-on-cash-tender-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470419\" data-ts=\"1560260445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRV\" target=\"_blank\">CTRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470419-contravir-up-21-on-positive-crv431-data-in-hepatitis-b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraVir up 21% on positive CRV431 data in hepatitis B</a></h4><ul><li>Thinly traded nano cap ContraVir Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a> <font color=\"green\">+21.4%</font>) is up average volume in early trade in apparent response to <a href=\"https://seekingalpha.com/pr/17540533-contravir-pharmaceuticals-announces-publication-crv431-data-experimental-model-hepatitis-b\" target=\"_blank\">just-published research</a> on cyclophilin inhibitor CRV431 in a mouse model of hepatitis B &#40;HBV&#41;.</li><li>The data, appearing in <em>PLOS ONE</em>, showed that CRV431 significantly reduced HBV DNA in the liver of transgenic mice in a dose-dependent manner while also reducing serum levels of surface antigen (HBsAg) (surface antigen signifies an active infection).</li><li>CRV431 is currently in <a href=\"https://clinicaltrials.gov/ct2/show/NCT03596697?term=crv431&amp;rank=1\" target=\"_blank\">Phase 1</a> development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470419\" data-linked=\"ContraVir up 21% on positive CRV431 data in hepatitis B\" data-tweet=\"$CTRV $HEPA - ContraVir up 21% on positive CRV431 data in hepatitis B https://seekingalpha.com/news/3470419-contravir-up-21-on-positive-crv431-data-in-hepatitis-b?source=tweet\" data-url=\"https://seekingalpha.com/news/3470419-contravir-up-21-on-positive-crv431-data-in-hepatitis-b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470414\" data-ts=\"1560259517\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470414-jaguar-health-up-60-premarket-on-niaid-support-for-cholera-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health up 60% premarket on NIAID support for cholera candidate</a></h4><ul><li>Thinly traded micro cap Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) is up <font color=\"green\">60% </font>premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17540445-jaguar-health-subsidiary-receiving-preclinical-services-funded-national-institute-allergy\" target=\"_blank\">announcement </a>that the U.S. NIH's National Institute of Allergy and Infectious Diseases &#40;NIAID&#41; will provide preclinical services to subsidiary Napo Pharmaceuticals to support the development of lechlemer for the treatment of cholera.</li><li>Specifically, NIAID-funded contractors will conduct toxicology testing for seven-day rat and dog studies.</li><li>Lechlemer is a botanical extract from the <em>Croton lechleri</em> tree, the same source for <a href=\"https://mytesi.com/\" target=\"_blank\">Mytesi </a>(crofelemer).</li></ul><div class=\"tiny-share-widget\" data-id=\"3470414\" data-linked=\"Jaguar Health up 60% premarket on NIAID support for cholera candidate\" data-tweet=\"$JAGX - Jaguar Health up 60% premarket on NIAID support for cholera candidate https://seekingalpha.com/news/3470414-jaguar-health-up-60-premarket-on-niaid-support-for-cholera-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3470414-jaguar-health-up-60-premarket-on-niaid-support-for-cholera-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470412\" data-ts=\"1560259477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470412-credit-suisse-resets-expectations-on-fedex-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse resets expectations on FedEx lower</a></h4><ul> <li>Credit Suisse lowers revenue and EPS estimates on FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>). The firm also reels in its price target on the shipper to $184 from $241 (still repping ~14% upside potential) .</li> <li>The firm says its call on FedEx is tied to deceleration in the U.S. and global macro issues, along with temporary volume and cost headwinds.</li> <li>Shares of FDX are <font color=\"green\">up 1.34%</font> premarket to $164.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470412\" data-linked=\"Credit Suisse resets expectations on FedEx lower\" data-tweet=\"$FDX - Credit Suisse resets expectations on FedEx lower https://seekingalpha.com/news/3470412-credit-suisse-resets-expectations-on-fedex-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3470412-credit-suisse-resets-expectations-on-fedex-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470411\" data-ts=\"1560259322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYV\" target=\"_blank\">LYV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470411-live-nationplus-1_8-atlantic-equities-starting-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Live Nation +1.8% with Atlantic Equities starting at Buy</a></h4><ul>   <li>Live Nation Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/LYV' title='Live Nation Entertainment, Inc.'>LYV</a>) is <font color=\"green\">up 1.8%</font> premarket following an initiation at Overweight by Atlantic Equities.</li>    <li>The firm set its price target at $75, implying 21% upside.</li>    <li>After hitting a December low, shares are <font color=\"green\">up 25.4%</font> YTD; they're <font color=\"green\">up 36.7%</font> over the past year.</li>  <li>Live Nation currently has a <a href=\"https://seekingalpha.com/symbol/LYV/ratings/sell-side-ratings\" target=\"_blank\">sell-side average rating of Outperform</a>, Seeking Alpha Authors' <a href=\"https://seekingalpha.com/symbol/LYV/ratings/author-ratings#filter=all\" target=\"_blank\">average rating of Neutral</a>, and <a href=\"https://seekingalpha.com/symbol/LYV/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470411\" data-linked=\"Live Nation +1.8% with Atlantic Equities starting at Buy\" data-tweet=\"$LYV - Live Nation +1.8% with Atlantic Equities starting at Buy https://seekingalpha.com/news/3470411-live-nationplus-1_8-atlantic-equities-starting-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3470411-live-nationplus-1_8-atlantic-equities-starting-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470410\" data-ts=\"1560259282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470410-mt-zyne-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MT, ZYNE among premarket gainers</a></h4><ul><li>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"green\">+56%</font> as its subsidiary <a href=\"https://seekingalpha.com/pr/17540445-jaguar-health-subsidiary-receiving-preclinical-services-funded-national-institute-allergy\" target=\"_blank\">receives</a> preclinical services funded by the National Institute of Allergy and Infectious Diseases.</li><li>NovaBay Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a>) <font color=\"green\">+34%</font>.</li><li>Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings, Inc.'>MOTS</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3470375-motus-gi-21-percent-premarket-fda-nod-next-gen-pure-vu\" target=\"_blank\">FDA nod</a> for next-gen Pure-Vu.</li><li>ContraVir Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRV' title='ContraVir Pharmaceuticals, Inc.'>CTRV</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/pr/17540533-contravir-pharmaceuticals-announces-publication-crv431-data-experimental-model-hepatitis-b\" target=\"_blank\">publication</a> of CRV431 data from experimental model of Hepatitis B.</li><li>Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3470376-zynerba-nabs-new-patent-u-s-shares-5-percent-premarket\" target=\"_blank\">new patent</a> in U.S.</li><li>ArcelorMittal (NYSE:<a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a>) <font color=\"green\">+7%</font> as <a href=\"https://seekingalpha.com/news/3470377-china-iron-ore-surges-supply-crunch-concerns\" target=\"_blank\">China iron ore surges</a> on supply crunch concerns.</li><li>Provention Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVB' title='Provention Bio, Inc.'>PRVB</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3470298-provention-files-5_5m-share-stock-offering\" target=\"_blank\">stock offering</a>.</li><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>) <font color=\"green\">+6%</font> as CymaBay Therapeutics <a href=\"https://seekingalpha.com/news/3470395-cymbays-pain-vikings-gain-9-percent-premarket\" target=\"_blank\">reported</a> underwhelming 12-week data on NASH candidate seladelpar.</li><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+5%</font> as Compass Point <a href=\"https://seekingalpha.com/news/3470284-new-age-beverages-plus-3_5-percent-compass-point-starts-buy\" target=\"_blank\">starts</a> at Buy.</li><li>Grubhub (NYSE:<a href='https://seekingalpha.com/symbol/GRUB' title='Grubhub Inc.'>GRUB</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470410\" data-linked=\"MT, ZYNE among premarket gainers\" data-tweet=\"$JAGX $NBY $MOTS - MT, ZYNE among premarket gainers https://seekingalpha.com/news/3470410-mt-zyne-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470410-mt-zyne-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470409\" data-ts=\"1560259019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470409-hds-symc-and-bynd-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HDS, SYMC and BYND among premarket losers</a></h4><ul><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-45%</font> on <a href=\"https://seekingalpha.com/news/3470340-cymabay-40-percent-premarket-disappointing-data-nash-candidate-seladelpar\" target=\"_blank\">disappointing data</a> on NASH candidate seladelpar.</li><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) <font color=\"red\">-19%</font>.</li><li>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"red\">-11%</font> on analyst <a href=\"https://seekingalpha.com/news/3470326-jpmorgan-downgrades-beyond-meat-valuation-call\" target=\"_blank\">downgrade</a>.</li><li>Genfit SA (NASDAQ:<a href='https://seekingalpha.com/symbol/GNFT' title='Genfit SA'>GNFT</a>) <font color=\"red\">-10%</font>.</li><li>HD Supply Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/HDS' title='HD Supply Holdings, Inc.'>HDS</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3470355-hd-supply-minus-3_6-percent-lowered-guidance-range\" target=\"_blank\">lowered guidance</a>.</li><li>Urban One (NASDAQ:<a href='https://seekingalpha.com/symbol/UONE' title='Urban One, Inc.'>UONE</a>) <font color=\"red\">-7%</font>.</li><li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <font color=\"red\">-6%</font> on new <a href=\"https://seekingalpha.com/news/3470339-symantec-minus-4_6-percent-new-street-low-target\" target=\"_blank\">Street-low target</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470409\" data-linked=\"HDS, SYMC and BYND among premarket losers\" data-tweet=\"$CBAY $ACHV $BYND - HDS, SYMC and BYND among premarket losers https://seekingalpha.com/news/3470409-hds-symc-and-bynd-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3470409-hds-symc-and-bynd-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470408\" data-ts=\"1560259005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEAL\" target=\"_blank\">ZEAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470408-zealand-up-2-premarket-on-positive-dasiglucagon-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zealand up 2% premarket on positive dasiglucagon data</a></h4><ul><li>Thinly traded Zealand Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEAL' title='Zealand Pharma A/S'>ZEAL</a>) is up <font color=\"green\">2%</font> premarket on light volume in response to <a href=\"https://seekingalpha.com/pr/17539929-zealand-pharma-presents-dasiglucagon-pivotal-phase-3-trial-data-79th-scientific-sessions\" target=\"_blank\">additional data</a> from a Phase 3 clinical trial evaluating a single dose of dasiglucagon as a rescue treatment in diabetic patients with severe hypoglycemia (low blood sugar). The results were presented at the American Diabetes Association Scientific Sessions in San Francisco.</li><li>The study showed that dasiglucagon rapidly increased blood sugar levels in type 1 diabetics experiencing very low levels of plasma glucose. The mean time to recovery was 10 minutes. Almost all (99%) recovered within 15 minutes.</li><li>The company plans to file a U.S. marketing application in early 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470408\" data-linked=\"Zealand up 2% premarket on positive dasiglucagon data\" data-tweet=\"$ZEAL - Zealand up 2% premarket on positive dasiglucagon data https://seekingalpha.com/news/3470408-zealand-up-2-premarket-on-positive-dasiglucagon-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3470408-zealand-up-2-premarket-on-positive-dasiglucagon-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470405\" data-ts=\"1560258595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGCY\" target=\"_blank\">LGCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470405-legacy-reserves-plans-to-file-for-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Legacy Reserves plans to file for bankruptcy</a></h4><ul><li>Legacy Reserves (NASDAQ:<a href='https://seekingalpha.com/symbol/LGCY' title='Legacy Reserves Inc.'>LGCY</a>) <font color=\"red\">-38.2%</font> pre-market after saying it expects to <a href=\"https://seekingalpha.com/pr/17540101-legacy-reserves-inc-reaches-agreement-rbl-second-lien-lenders-terms-financial-restructuring\" target=\"_blank\">file for Chapter 11 bankruptcy</a>, as it implements a restructuring support agreement with its lenders.</li><li>LGCY says the plan will provide for de-leveraging of its capital structure by more than $900M, including an infusion of at least $200M in equity capital, and payment in full of its other secured creditors, tax and other claimants, trade creditors and employees.</li><li>The restructuring agreement plans for LGCY to obtain debtor-in possession financing provided by certain lenders under its reserve based revolving credit facility.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470405\" data-linked=\"Legacy Reserves plans to file for bankruptcy\" data-tweet=\"$LGCY - Legacy Reserves plans to file for bankruptcy https://seekingalpha.com/news/3470405-legacy-reserves-plans-to-file-for-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3470405-legacy-reserves-plans-to-file-for-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>163&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470404\" data-ts=\"1560258434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTR\" target=\"_blank\">DLTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470404-dollar-treeplus-4-after-jpmorgan-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dollar Tree +4% after JPMorgan upgrade</a></h4><ul> <li>JPMorgan upgrades Dollar Tree (NASDAQ:<a href='https://seekingalpha.com/symbol/DLTR' title='Dollar Tree, Inc.'>DLTR</a>) to an Overweight rating and assigns a price target of <a href=\"https://www.cnbc.com/2019/06/11/calls-of-the-day-beyond-meat-facebook-lyft-jetblue-more.html\" target=\"_blank\">$122</a>.</li> <li>\"Our top-line and margin builds across banners support an inflection to high-single net income growth and low-double-digit consolidated EPS growth beyond FY19,\" notes JP.</li> <li>The firm says the combination of Dollar Tree stability and Family Dollar's self-help story could drive +$1B annual free cash flow generation by FY20 in a stable/rational low-end backdrop (wages/employment) translating to an overall attractive fundamental risk/reward profile on the retailer.</li> <li>The average sell-side rating on Dollar Tree is Outperform and the SA Authors' consensus rating is Bullish, while the <a href=\"https://seekingalpha.com/symbol/DLTR/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> on DLTR is Neutral.</li> <li>Shares of Dollar Tree are <font color=\"green\">up 3.59%</font> premarket to $107.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3470404\" data-linked=\"Dollar Tree +4% after JPMorgan upgrade\" data-tweet=\"$DLTR - Dollar Tree +4% after JPMorgan upgrade https://seekingalpha.com/news/3470404-dollar-treeplus-4-after-jpmorgan-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3470404-dollar-treeplus-4-after-jpmorgan-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470396\" data-ts=\"1560257998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LK\" target=\"_blank\">LK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470396-luckin-coffee-attracts-new-bulls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Luckin Coffee attracts new bulls</a></h4><ul> <li>Luckin Coffee (NASDAQ:<a href='https://seekingalpha.com/symbol/LK' title='Luckin Coffee Inc.'>LK</a>) is on watch after the Chinese coffee chain attracts more sell-side coverage.</li> <li>Needham starts off Luckin with a Buy rating and price target of $27, calling it the only local brand with strong national exposure. \"By utilizing its new technology-driven retail model and providing high-quality coffee products, affordability, and convenience to customers, we believe Luckin is disrupting the coffee industry in China,\" notes the firm.</li> <li>KeyBanc launches coverage on Luckin with an Overweight rating. \"We believe the company has several strategic advantages that should support its transition into a profitable business. These include: 1) exposure to a rapidly evolving coffee culture in China; 2) limited direct competition; 3) low development costs; 4) better tech and data analytics than peers; and 5) low per-unit cost structure,\" notes the KeyBanc analyst team.</li> <li>Morgan Stanley is a bit more cautious with Luckin, initiating at Equal-weight and assigning a price target of $21.</li>  <li>Shares of Luckin are <font color=\"green\">up 1.21%</font> premarket to $18.76. The post-IPO trading range is $13.71 to $25.96 after the pricing went off at $17.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470396\" data-linked=\"Luckin Coffee attracts new bulls\" data-tweet=\"$LK - Luckin Coffee attracts new bulls https://seekingalpha.com/news/3470396-luckin-coffee-attracts-new-bulls?source=tweet\" data-url=\"https://seekingalpha.com/news/3470396-luckin-coffee-attracts-new-bulls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470395\" data-ts=\"1560257986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VKTX\" target=\"_blank\">VKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470395-cymbays-pain-is-vikings-gain-up-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymBay&#39;s pain is Viking&#39;s gain, up 9% premarket</a></h4><ul><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics, Inc.'>VKTX</a>) is up <font color=\"green\">9%</font> premarket on average volume in apparent response to CymaBay Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">44%</font> plummet after it <a href=\"https://seekingalpha.com/news/3470340-cymabay-40-percent-premarket-disappointing-data-nash-candidate-seladelpar\" target=\"_blank\">reported </a>underwhelming 12-week data on NASH candidate seladelpar.</li><li>Two months ago, Viking <a href=\"https://seekingalpha.com/news/3449927-viking-ahead-7-percent-premarket-new-vk2809-data\" target=\"_blank\">reported </a>updated 12-week data on NASH candidate VK2809 that showed a much more profound treatment effect with a favorable safety profile.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470395\" data-linked=\"CymBay&#39;s pain is Viking&#39;s gain, up 9% premarket\" data-tweet=\"$VKTX $CBAY - CymBay&#39;s pain is Viking&#39;s gain, up 9% premarket https://seekingalpha.com/news/3470395-cymbays-pain-is-vikings-gain-up-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3470395-cymbays-pain-is-vikings-gain-up-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470394\" data-ts=\"1560257799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470394-vivus-launches-online-platform-to-purchase-qsymia-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VIVUS launches online platform to purchase Qsymia; shares up 4% premarket</a></h4><ul> <li>VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) has <a href=\"https://seekingalpha.com/pr/17540251-vivus-reduces-barrier-achieving-healthy-weight-goals-launch-online-platform-purchase-qsymia\" target=\"_blank\">launched</a> an e-medicine platform that will enable patients with a prescription for Qsymia (phentermine and topiramate extended-release) capsules CIV to purchase the medication online.</li>             <li>With the Qsymia Advantage Program, new and existing patients can receive their monthly medication for $98 plus shipping and handling, a 30% or greater reduction.</li>    <li>Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m<em><sup>2</sup></em> or greater or 27 kg/m<em><sup>2</sup></em> or greater in the presence of at least blood pressure, type 2 diabetes, or high cholesterol.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3470394\" data-linked=\"VIVUS launches online platform to purchase Qsymia; shares up 4% premarket\" data-tweet=\"$VVUS - VIVUS launches online platform to purchase Qsymia; shares up 4% premarket https://seekingalpha.com/news/3470394-vivus-launches-online-platform-to-purchase-qsymia-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3470394-vivus-launches-online-platform-to-purchase-qsymia-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470387\" data-ts=\"1560257204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470387-barclays-bearish-on-teva-sees-14-downside-risk-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays bearish on Teva, sees 14% downside risk in premarket analyst action</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies, Inc.'>A</a>) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray.</li><li>Danaher (NYSE:<a href='https://seekingalpha.com/symbol/DHR' title='Danaher Corporation'>DHR</a>) initiated with Neutral rating and $148 (7% upside) price target at Piper.</li><li>Teleflex (NYSE:<a href='https://seekingalpha.com/symbol/TFX' title='Teleflex Incorporated'>TFX</a>) initiated with Outperform rating and $345 (11% upside) price target at Wells Fargo.</li><li>Barclays has been busy:</li><li>Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) resumed with Underweight rating and $133 (5% upside).</li><li>AMAG Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAG' title='AMAG Pharmaceuticals, Inc.'>AMAG</a>) resumed with Overweight rating and $19 (102% upside) price target.</li><li>Jazz Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals plc'>JAZZ</a>) resumed with Overweight rating and $164 (27% upside) price target.</li><li>Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) resumed with Equal Weight rating and $6 (27% upside) price target.</li><li>Ligand Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a>) initiated with Equal Weight rating and $131 (18% upside) price target.</li><li>Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a>) resumed with Equal Weight rating and $11 (16% upside) price target.</li><li>Mylan N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan N.V.'>MYL</a>) resumed with Overweight rating and $26 (48% upside) price target. Shares up <font color=\"green\">2%</font> premarket.</li><li>Phibro Animal Health (NASDAQ:<a href='https://seekingalpha.com/symbol/PAHC' title='Phibro Animal Health Corporation'>PAHC</a>) resumed with Underweight rating and $25 (16% downside risk) price target.</li><li>Pacira BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/PCRX' title='Pacira BioSciences, Inc.'>PCRX</a>) resumed with Overweight rating and $52 (21% upside) price target.</li><li>Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) resumed with Overweight rating and $28 (162% upside) price target.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) resumed with Underweight rating and $8 (14% downside risk) price target.</li><li>Zoetis (NYSE:<a href='https://seekingalpha.com/symbol/ZTS' title='Zoetis Inc.'>ZTS</a>) resumed with Overweight rating and $120 (9% upside) price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470387\" data-linked=\"Barclays bearish on Teva, sees 14% downside risk in premarket analyst action\" data-tweet=\"$A $DHR $TFX - Barclays bearish on Teva, sees 14% downside risk in premarket analyst action https://seekingalpha.com/news/3470387-barclays-bearish-on-teva-sees-14-downside-risk-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3470387-barclays-bearish-on-teva-sees-14-downside-risk-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470384\" data-ts=\"1560257007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIM\" target=\"_blank\">KIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470384-bofaml-takes-action-on-reit-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML takes action on REIT ratings</a></h4><ul><li>A crop of REIT <a href=\"https://www.marketbeat.com/ratings/USA/latest/\" target=\"_blank\">upgrades/downgrades</a> from Bank of America Merrill Lynch:</li><li>Brandywine Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/BDN' title='Brandywine Realty Trust'>BDN</a>) cut to underperform from neutral.</li><li>Kimco (NYSE:<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a>) boosted to buy from neutral; KIM<font color=\"green\"> rises 0.9%</font> in premarket trading to $18.40.</li><li>Vereit (NYSE:<a href='https://seekingalpha.com/symbol/VER' title='VEREIT, Inc.'>VER</a>) raised to buy from underperform; VER jumps <font color=\"green\">1.4%</font> to $9.16.</li><li>Separately, Citi cuts American Homes 4 Rent (NYSE:<a href='https://seekingalpha.com/symbol/AMH' title='American Homes 4 Rent'>AMH</a>) to neutral from buy; AMH <font color=\"red\">slips 0.9% </font>to $24.57.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3470334-bofa-merrill-analyst-upgrades-essential-properties-downgrades-epr-properties\" target=\"_blank\">BofA/Merrill analyst upgrades Essential Properties and downgrades EPR Properties</a> (June 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3470384\" data-linked=\"BofAML takes action on REIT ratings\" data-tweet=\"$KIM $VER $BDN - BofAML takes action on REIT ratings https://seekingalpha.com/news/3470384-bofaml-takes-action-on-reit-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3470384-bofaml-takes-action-on-reit-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470377\" data-ts=\"1560256162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470377-china-iron-ore-surges-on-supply-crunch-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China iron ore surges on supply crunch concerns</a></h4><ul><li>Global metals and mining stocks trade higher after <a href=\"https://www.reuters.com/article/us-asia-ironore/dalian-iron-ore-surges-on-supply-crunch-worries-idUSKCN1TC0R1\" target=\"_blank\">China iron ore futures jump 6%</a> on speculation that demand will continue to exceed production over the coming months: <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color=\"green\">+6.3%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs Inc.'>CLF</a> <font color=\"green\">+4.8%</font>, <a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color=\"green\">+4.1%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corporation'>AKS</a> <font color=\"green\">+3.9%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color=\"green\">+3.7%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Group'>BHP</a> <font color=\"green\">+3.2%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color=\"green\">+2.9%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto Group'>RIO</a> <font color=\"green\">+2.7%</font>, <a href='https://seekingalpha.com/symbol/XME' title='SPDR S&P Metals and Mining ETF'>XME</a> <font color=\"green\">+2.6%</font>.</li><li>Reuters reports the most-traded iron ore futures on the Dalian Commodity Exchange hit a  daily upper-trading limit with a 6% rally to 760.5 yuan/mt ($109.97); benchmark Shanghai rebar prices rose 3.5% and hot-rolled coil climbed 2.7%.</li><li>\"Tight supply is unlikely to be eased in the short term, but demand for  iron ore will be robust despite the moderation of profit margins at  steel mills,\" according to analysts from Huatai Futures.</li><li>Inventory of imported iron ore at Chinese ports reportedly has fallen to 121.6M metric tons, its lowest level in two and a half years, while utilization rates at steel mills across China stood at a relatively high  71.44% as of June 7, according to data from Mysteel, underlining strong demand for the ferrous metal, although mills  in the top steelmaking city of Tangshan have been ordered to reduce production in June.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470377\" data-linked=\"China iron ore surges on supply crunch concerns\" data-tweet=\"$MT $FCX $X - China iron ore surges on supply crunch concerns https://seekingalpha.com/news/3470377-china-iron-ore-surges-on-supply-crunch-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3470377-china-iron-ore-surges-on-supply-crunch-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470376\" data-ts=\"1560256097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYNE\" target=\"_blank\">ZYNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470376-zynerba-nabs-new-patent-in-u-s-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba nabs new patent in U.S.; shares up 5% premarket</a></h4><ul> <li>The USPTO has <a href=\"https://seekingalpha.com/pr/17540176-zynerba-pharmaceuticals-receives-new-u-s-patent-treatment-autism-spectrum-disorder\" target=\"_blank\">issued</a> Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals, Inc.'>ZYNE</a>), Patent No. 10,314,792, titled \u201cTreatment of Autism Spectrum Disorder with Cannabidiol\u201d which includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol.</li>   <li>The new patent will expire in 2038.</li>  <li>The issuance of this patent comes as enrollment progresses in Phase 2 BRIGHT study evaluating the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder.</li><li>Shares are up <font color=\"green\">5%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3470376\" data-linked=\"Zynerba nabs new patent in U.S.; shares up 5% premarket\" data-tweet=\"$ZYNE - Zynerba nabs new patent in U.S.; shares up 5% premarket https://seekingalpha.com/news/3470376-zynerba-nabs-new-patent-in-u-s-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3470376-zynerba-nabs-new-patent-in-u-s-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470375\" data-ts=\"1560256030\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOTS\" target=\"_blank\">MOTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470375-motus-gi-up-21-premarket-on-fda-nod-for-next-gen-pure-vu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Motus GI up 21% premarket on FDA nod for next-gen Pure-Vu</a></h4><ul><li>Thinly traded nano cap Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings, Inc.'>MOTS</a>) is up <font color=\"green\">21% </font>premarket on increased volume in reaction to its <a href=\"https://seekingalpha.com/pr/17540228-motus-gi-receives-fda-clearance-market-pure-vu-gen2\" target=\"_blank\">announcement </a>that the FDA has granted 510(k) clearance for its next-generation Pure-Vu System used to facilitate the cleaning of a poorly prepared colon during a colonoscopy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470375\" data-linked=\"Motus GI up 21% premarket on FDA nod for next-gen Pure-Vu\" data-tweet=\"$MOTS - Motus GI up 21% premarket on FDA nod for next-gen Pure-Vu https://seekingalpha.com/news/3470375-motus-gi-up-21-premarket-on-fda-nod-for-next-gen-pure-vu?source=tweet\" data-url=\"https://seekingalpha.com/news/3470375-motus-gi-up-21-premarket-on-fda-nod-for-next-gen-pure-vu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470373\" data-ts=\"1560255784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VFF\" target=\"_blank\">VFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470373-texas-governor-signs-house-bill-1325-legalizing-hemp-cultivation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas governor signs House Bill 1325 legalizing hemp cultivation</a></h4><ul> <li>Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <a href=\"https://seekingalpha.com/pr/17540159-village-farms-international-announces-texas-governor-signs-house-bill-1325-law-legalizing\" target=\"_blank\">announces</a> that Governor Greg Abbott has signed into law Texas House Bill 1325, which effectively legalizes the cultivation and processing of hemp and hemp-derived products, including cannabidiol &#40;CBD&#41; in the State.</li> <li>In anticipation of the passage of the legislation, Village Farms has begun conversion of half of its 1.3M square foot, Permian Basin greenhouse for cultivation of high-CBD hemp and CBD extraction.</li><li>The Texas Hemp Legislation will require licenses and Village Farms plans to apply for the same. No time frame has yet been provided by the State of Texas for the licensing process.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3470373\" data-linked=\"Texas governor signs House Bill 1325 legalizing hemp cultivation\" data-tweet=\"$VFF - Texas governor signs House Bill 1325 legalizing hemp cultivation https://seekingalpha.com/news/3470373-texas-governor-signs-house-bill-1325-legalizing-hemp-cultivation?source=tweet\" data-url=\"https://seekingalpha.com/news/3470373-texas-governor-signs-house-bill-1325-legalizing-hemp-cultivation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470372\" data-ts=\"1560255674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470372-creeminus-6_6-on-q4-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree -6.6% on Q4 guidance cut</a></h4><ul><li>Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) <a href=\"https://seekingalpha.com/pr/17540306-cree-updates-q4-fy-2019-financial-guidance\" target=\"_blank\">updates</a> its Q4 outlook primarily due to the U.S. actions against Huawei. The company planned on $15M in Q4 revenue from products and materials sold to Huawei.</li><li>The LED products view is cut due to softer than expected demand due to trade uncertainty.</li><li>Cree now expects revenue from continuing operations of $245-252M (was: $263-271M) with Wolfspeed sales of $132-135M and LED revenue of $113-117M.</li><li>Non-GAAP EPS is expected between $0.08 to $0.12 (was: $0.12 to $0.16).</li><li>Cree shares are<font color=\"red\"> down 6.6%</font> pre-market to $55.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470372\" data-linked=\"Cree -6.6% on Q4 guidance cut\" data-tweet=\"$CREE - Cree -6.6% on Q4 guidance cut https://seekingalpha.com/news/3470372-creeminus-6_6-on-q4-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3470372-creeminus-6_6-on-q4-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470371\" data-ts=\"1560255515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470371-handr-block-eps-beats-0_20-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">H&amp;amp;R Block EPS beats by $0.20, beats on revenue</a></h4><ul><li>H&amp;R Block (NYSE:<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block, Inc.'>HRB</a>): Q4 GAAP EPS of $4.32 <font color=\"green\">beats by $0.20</font>.</li><li>Revenue of $2.33B (-2.5% Y/Y) <font color=\"green\">beats by $10M</font>.</li><li>Shares <font color=\"green\">+6.53%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17540448-h-and-r-block-reports-fiscal-2019-results-enters-agreement-acquire-wave-financial-announces\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3470371\" data-linked=\"H&amp;amp;R Block EPS beats by $0.20, beats on revenue\" data-tweet=\"$HRB - H&amp;R Block EPS beats by $0.20, beats on revenue https://seekingalpha.com/news/3470371-handr-block-eps-beats-0_20-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3470371-handr-block-eps-beats-0_20-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470367\" data-ts=\"1560255208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACHV\" target=\"_blank\">ACHV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470367-achieve-life-sciences-up-16-premarket-on-positive-cytisinicline-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achieve Life Sciences up 16% premarket on positive cytisinicline data</a></h4><ul><li>Achieve Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a>) is up <font color=\"green\">16%</font> premarket on robust volume in response to <a href=\"https://seekingalpha.com/pr/17540136-achieve-life-sciences-announces-statistically-significant-improvement-quit-rates-simplified\" target=\"_blank\">results </a>from the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03709823?term=achieve+life+sciences&amp;rank=2\" target=\"_blank\">ORCA-1</a> dose-selection study of cytisinicline for smoking cessation.</li><li>Three of the four treatment arms demonstrated statistically significant effects on reducing daily smoking compared to placebo.</li><li>Across all treatment arms over the 25-day treatment period, subjects receiving cytisinicline experienced a 74 - 80% median reduction in cigarettes smoked although those receiving placebo showed a 62% mean reduction.</li><li>The most significant treatment effect was the 3 mg TID (3x/day) arm that showed a 54% abstinence rate at week 4 compared to 16% for placebo (p&lt;0.0001).</li><li>The company says it has selected the 3.0 mg TID regimen for Phase 3 development.</li><li>No new safety signals were reported.</li><li>Additional data from ORCA-1 will be submitted for presentation at a future medical conference.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470367\" data-linked=\"Achieve Life Sciences up 16% premarket on positive cytisinicline data\" data-tweet=\"$ACHV - Achieve Life Sciences up 16% premarket on positive cytisinicline data https://seekingalpha.com/news/3470367-achieve-life-sciences-up-16-premarket-on-positive-cytisinicline-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3470367-achieve-life-sciences-up-16-premarket-on-positive-cytisinicline-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3470357\" data-ts=\"1560254307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYFT\" target=\"_blank\">LYFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3470357-lyftplus-4-susquehanna-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lyft +4% as Susquehanna turns bullish</a></h4><ul><li>Update with more info from the upgrade:</li><li>The firm says Lyft is \"showing clear evidence of marketing and insurance cost leverage.\"</li><li>Susquehanna sees the multiple re-rating higher with continuing revenue outperformance and improving profitability.</li><li><strong>Original:</strong> Susquehanna upgrades Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) from Neutral to Positive.</li><li>The target increases from $57 to $80, implying a 41% upside.</li><li>Lyft shares are <font color=\"green\">up 4%</font> pre-market to $59.</li><li>LYFT has an Outperform <a href=\"https://seekingalpha.com/symbol/LYFT/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3470357\" data-linked=\"Lyft +4% as Susquehanna turns bullish\" data-tweet=\"$LYFT - Lyft +4% as Susquehanna turns bullish https://seekingalpha.com/news/3470357-lyftplus-4-susquehanna-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3470357-lyftplus-4-susquehanna-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}